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ABSTRACT 
 
Fibulin-4 is an extracellular matrix protein required for the formation of the elastic 
fibers.  Human mutations in the fibulin-4 gene cause autosomal recessive cutis laxa with 
widespread systemic involvement and congenital presentation. To study the 
developmental functions of fibulin-4, I studied one of the two fibulin-4 genes, fbln4a. The 
mRNA for fbln4a RNA was expressed in the adaxial cells around the notochord during 
somite formation, and in the myosepta, head, and heart at later stages.  Fbln4a protein 
was localized to the notochord sheath starting from somite formation suggesting 
differential expression of fbln4a RNA and protein in the midline structures during 
development. To inactivate fbln4a in vivo, we used a retroviral mutant and an antisense 
morpholino oligonucleotide (MO) for transient knockdown.  Embryos homozygous for the 
fbln4a mutation showed a complete loss of the Fbln4a protein, but presented no obvious 
gross abnormalities.  However, fbln4a knockdown yielded cardiovascular and 
musculoskeletal defects at 2 days post fertilization including pooling of blood at the caudal 
vein plexus, vascular hemorrhage in the head, reduced circulation and heart rate, bent 
notochord, rounded somites and reduced embryo length.  All of these features were 
rescued by co-injection of fbln4a mRNA with the MO. Early cardiac and vascular 
progenitor markers showed an expansion of the heart field and reduction of the vascular 
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fields in knockdown embryos. Homozygous mutants were resistant, whereas 
heterozygotes were sensitized to the effect of fbln4a MO, protective compensatory 
mechanisms as a possible reason for phenotypic discrepancy between fbln4a mutant and 
knockdown animals. Inhibition of transforming growth factor beta (Tgfb) signaling with a 
small molecule rescued both the cardiovascular and connective tissue anomalies in 
knockdown embryos.  By varying the period of treatment, I identified late gastrulation and 
early segmentation as the critical periods.  I conclude that Fbln4a inhibits Tgfb signals 
emanating from the notochord and regulates cardiac and vascular progenitor pools.  The 
public health significance of this work is the identification of Tgfb inhibition as a candidate 
approach for treating of fibulin-4-related cutis laxa, an orphan disease for which no 
treatment has been available to date. 
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1.0  INTRODUCTION 
1.1 EXTRACELLULAR MATRIX  
The extracellular matrix (ECM) is a complex network of proteins, glycoproteins and 
proteoglycans,  which provides scaffolding and structural support to cells and organs.  
The ECM endows tissues with the mechanical strength necessary through life.  The ECM 
is versatile in composition, enabling specialized adaptation to the functional requirements 
of each particular tissue (Bosman and Stamenkovic 2003).    Additionally, it is capable of 
exchanging information with cells and modulating a whole host of processes including 
cell migration, attachment, differentiation, repair and survival.  Identification of ECM 
proteins remains a challenging task due to the insoluble and frequently cross-linked 
nature of these proteins.   So far a repertoire of more than 300 proteins has been identified 
in matrices of mammals and is called the “core matrisome” (Hynes and Naba 2012).  The 
list comprises of almost 300 proteins,  including 43 collagen subunits, three dozen 
proteoglycans and around 200 glycoproteins.  In addition, there are numerous proteins 
that have been found associated with ECM, such as ECM-modifying enzymes, growth 
factors and cytokines (Hynes and Naba 2012).  The main components of ECM include 
collagens, laminins, fibronectin, proteoglycans, and elastin.  Elastin is an insoluble protein 
which, together with scaffold-forming fibrillin microfibrils makes elastic fibers.  These 
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assemblies provide resilience to connective tissues, and will be further discussed in the 
next section. 
1.2 ELASTIC FIBERS 
Elastic fibers are one of the major ECM macromolecular components that are vital for 
endowing tissues, such as blood vessels, skin and lungs with elastic properties which are 
essential for their dynamic functions (Sato, Wachi et al. 2007).  During evolution, elastic 
fibers enabled transition from open to the closed circulatory system in vertebrates, which 
bear high pulsatile pressures (Wagenseil and Mecham 2009).  Elastic fibers provide 
expansion and recoil properties to large arteries, aorta and pulmonary arteries during 
heart contraction and relaxation, and therefore help maintain blood pressure within the 
cardiovascular system.   
Elastic fibers adopt tissue-specific networks that depend on the elastic 
requirements of a particular tissue.  In blood vessels, where elastic fibers account for up 
to 50% of dry weight elastin forms layers, known as lamellae in the tunica media 
(Wagenseil and Mecham, 2009).  In the dermis of the skin, elastin is less abundant (2%), 
but it provides resistance to deformational forces by forming thick interlaced fibers that 
become thinner towards the surface of the skin (Kielty, Wess et al. 2002).  In the lungs, 
similar to the skin, elastic fibers comprise approximately 2% of the dry weight, forming a 
thin, highly branched structures located at the tips of the alveolar septa and a highly 
connected network that links the respiratory tissues and provide expansion and recoil 
properties to the lungs (Shifren and Mecham 2006).  In addition to their structural and 
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mechanical roles, elastic fibers regulate the bioavailability of growth factors and the 
adhesion of cells.  In particular, they regulate activation and signaling of transforming 
growth factor beta (TGFβ) family, and interact with integrins and syndecans, thereby 
directing cell adhesion, cell survival, proliferation and migration (Bax, Mahalingam et al. 
2007). 
1.2.1 MAJOR STRUCTURAL COMPONENTS OF ELASTIC FIBRES  
Elastic fibers contain two major components distinguishable by electron microscopy: 
elastin, a hydrophobic cross-linked polymer which forms the core of the structure, and 
fibrillin-rich microfibrils which are partly embedded in and partly surround elastin (Kielty, 
Sherratt et al. 2002).  Following a more detailed introduction to the structural proteins 
fibrillins and elastin, I will introduce the most relevant of the more than thirty identified 
elastic fibers associated components, including a family of cross-linking enzymes, lysyl 
oxidase (LOX) and LOX-like proteins, and proteins that facilitate elastic fiber assembly, 
namely fibulins and latent transforming growth factor binding proteins (LTBPs).   
1.2.1.1 Tropoelastin and elastin 
The precursor of polymeric elastin is a 72 KDa soluble protein called tropoelastin.  
Tropoelastin is synthesized by fibroblasts, lung alveolar cells, chondrocytes and vascular 
smooth muscle cells (Martin, Vrhovski et al. 1995), and contains alternating hydrophobic 
and hydrophilic domains.  It has a remarkable biophysical property of coacervation, which 
is dependent on concentration, temperature, ionic strength and pH.  When a tropoelastin 
solution is warmed at 37°C at pH 7, it undergoes a phase transition, forming an emulsion 
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of droplets with high protein concentration suspended in a solution of low tropoelastin 
content (Vrhovski and Weiss 1998).  Coacervation is highly reversible and is enabled by 
interactions between the hydrophobic domains of tropoelastin.  Although self-association 
of tropoelastin through coacervation is thought to be necessary, it is not sufficient for 
formation of elastic fibers.  Tropoelastin aggregates need to be deposited onto microfibrils 
in an orderly and uniform fashion and have to be crosslinked through their exposed, 
hydrophilic, lysine-rich crosslinking domains (Clarke, Arnspang et al. 2006).  An overview 
of the process of elastic fiber assembly is shown in section 1.2.2.  Elastin is the most 
abundant ECM protein in the aorta and great arteries where it provides elasticity and 
recoil.  Elastin null mice die perinatally due to severe obstructive vascular disease 
associated with increased proliferation and disorganization of smooth muscle cells (Li, 
Brooke et al. 1998), and also fail to develop alveoli in the lungs (Wendel, Taylor et al. 
2000).  Heterozygous mice, however, survive well into adulthood and exhibit 
hypertension, associated with increased number of elastic lamellae in the aorta and large 
arteries, and decreased size of blood vessels at normal blood pressure (Wagenseil, 
Nerurkar et al. 2005). 
1.2.1.2 Fibrillin-1 and microfibrils 
Fibrillin-1 is a large ECM glycoprotein (~ 350 KDa) and the major component of the 
microfibrillar scaffold (Handford, Downing et al. 2000).  In elastic tissues, this scaffold is 
essential for elastin fiber assembly as it acts as a template upon which tropoelastin gets 
deposited and crosslinked (Kielty, Wess et al. 2002).  Mice lacking fibrillin-1 die perinatally 
due to vascular and pulmonary complications, related to abnormal elastic fibers, 
emphasizing the importance of fibrillin-1 in elastogenesis (Carta, Pereira et al. 2006). 
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Microfibril formation is facilitated by the self-assembly of fibrillin-1 via N- and C- terminal 
interactions, yielding a characteristic beads-on-a-string structure that can be visualized 
by rotary shadowing electron microscopy.  Fibrillinogenesis depends on the pre-existing 
fibronectin network, without which fibrillin-1 microfibrils cannot be formed by cultured cells 
(Marson, Rock et al. 2005).  Fibrillin-1 binds to latent TGFβ binding proteins LTBPs -1, -
3, and -4, which control secretion, bioavailability and activation of latent TGFβ, but also 
have distinct roles in ECM organization (Todorovic and Rifkin 2012). 
1.2.1.3 Lysyl oxidase enzymes 
Lysyl oxidase (LOX) is a 30 KDa enzyme, which, together with four other LOX-like 
proteins (LOXL1-4), comprises of a family of copper-dependent enzymes (Grau-Bove, 
Ruiz-Trillo et al. 2015). LOX and four LOX-like enzymes (LOXLs) are responsible for 
crosslinking elastin.  LOXs oxidize the epsilon amino groups of lysines to aldehydes, 
which spontaneously condense to form elastin-specific covalent desmosine or 
isodesmosine crosslinks (Sato, Wachi et al. 2007).  The crosslinking domains in 
tropoelastin assume an α-helical secondary structure which places two lysines in one 
chain in close proximity to a pair of lysines on another chain to from the tetrafunctional 
crosslinks (Brown-Augsburger, Tisdale et al. 1995).  This process of crosslinking 
increases the stability of elastic fibers, preventing their degradation by proteinases 
(Romero, Tinker et al. 1986).  Two distinct knockout mouse lines implicated LOX in the 
development of the cardiovascular and respiratory systems, and the skin (Maki, Rasanen 
et al. 2002, Hornstra, Birge et al. 2003, Maki, Sormunen et al. 2005).  Desmosine levels 
were severely reduced indicating diminished crosslinking (~ 60% in aorta) in the mice 
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resulting in lethal abnormalities, including ruptured aortic aneurysms.   Mice deficient in 
LOXL1, a member of the LOX family with most similarity to LOX, exhibit cardiovascular 
and connective tissue defects, although they are viable and show a normal life span (Liu, 
Zhao et al. 2004).   
1.2.1.4 Fibulins 
Fibulins are a seven member ECM calcium-binding glycoproteins which interact with a 
range of ECM molecules, such as elastin, fibrillins, LOX, and fibronectin (Timpl, Sasaki 
et al. 2003, Kobayashi, Kostka et al. 2007). Through interacting with ECM components, 
fibulins are thought to be a bridge within the ECM, helping in assembly of structures of 
elastic fibers (de Vega, Iwamoto et al. 2009).  Fibulin-1 can be found in the elastin core, 
fibulin-2 and fibulin-5 at the interface of elastin core and microfibrils, and fibulin-4 within 
the bundles of microfibrils and all these proteins have been shown to bind to elastin 
(Kobayashi, Kostka et al. 2007).   Despite domain organization similarity amongst the 
fibulin protein family, knockout mice of fibulin -1 or -2 do not show altered elastogenesis, 
however knockouts of fibulins -3, -4, -5 have a deleterious effect of elastic fiber deposition 
(Kostka, Giltay et al. 2001, Nakamura, Lozano et al. 2002, McLaughlin, Chen et al. 2006, 
McLaughlin, Bakall et al. 2007, Horiguchi, Inoue et al. 2009).  Despite having high 
sequence similarity, fibulin-4 and fibulin-5, have distinct roles in elastogenesis due to 
differences in their binding characteristics to elastin and LOX.  Fibulin-5 binds to 
tropoelastin with high affinity than fibulin-4 (KD=64 nM, KD=131 nM, respectively) while 
LOX binds fibulin-4 strongly in comparison to fibulin-5 (KD= nM, KD=131 nM, 
respectively)(Choudhury, McGovern et al. 2009).  Fibulin-4 has been shown to facilitiate 
the elastin crosslinking step of elastic fiber assembly, whilst Fibulin-5 regulates the 
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deposition of elastin globules onto the  microfibrillar scaffold (Choudhury, McGovern et 
al. 2009).  
1.2.1.5 LTBPS 
Latent TGFβ binding proteins (LTBP) are secreted glycoproteins which are structurally 
homologous to fibrillin microfibrils with several conserved domains.  Major function of 
LTBPs is thought to be controlling secretion, bioavailability and activation of TGFβ in the 
ECM.  However,  LTBPs -1, -2, -4 have been implicated in elastic fiber assembly, due to 
their ability to interact with fibrillin-1 microfibril and their co-localization with microfibrils 
(Isogai, Ono et al. 2003, Hirani, Hanssen et al. 2007).  Further, LTBPs -1 and -4 have 
been shown to be assisting functions of fibulins -4 and -5, by inhibiting their binding to 
fibrillin-1 (Ono, Sengle et al. 2009) and LTBP-1 has been shown to be interacting with 
fibulin-4 and fibrilin-1 simultaneously.  Mutations in LTBP-4 lead to Urban-Rifkin-Davis 
syndrome in human, which is characterized by disorganized elastic fibers (Urban, 
Hucthagowder et al. 2009).  Mice lacking LTBP-4 exhibit similar elastic fiber deformation 
to that observed in mice lacking fibulin-4 or -5, confirming that LTBPs have an additional 
role in ECM than to controlling TGFβ signaling.  
1.2.2 ELASTIC FIBER ASSEMBLY 
Elastic fiber assembly is a complex and highly organized hierarchical process that occurs 
during the late fetal and early postnatal stages of mammalian development (Figure 1). 
The process of elastinogenesis starts with the production of fibrillin microfibrils which act 
as a scaffold onto which elastin is deposited (Sato, Wachi et al. 2007). Next, tropoelastin, 
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forms globular micro-aggregates, presumably through the process of coacervation 
(Clarke, Arnspang et al. 2006).  This process aligns tropoelastin appropriately for 
crosslinking and increases the affinity of tropoelastin to bind to LOXs (Vrhovski and Weiss 
1998).  Small covalently cross-linked elastin globules are then deposited on the microfibril 
template, where they further undergo maturation to produce a stable, continuous elastin 
core.  The merger of several elastic fibres to each other leads to the formation of a 
network, which endows organs the typical ability to withstand repeated cycles of stretch 
and recoil.  This, so called “macroassembly” of elastic fibers is dynamic, cell-directed 
process as demonstrated by time-lapse imaging of live cells (Czirok, Zach et al. 2006, 
Kozel, Rongish et al. 2006) 
9 
Figure 1.  Elastic fiber assembly model. 
Tropoelastin is secreted on the cell surface where it undergoes coacervation, forming droplets 
which are crosslinked by LOX.  Cross-linked elastin is then deposited onto the microfibrillar 
scaffold where it further gets crosslinked to form mature elastic fibers in the ECM.  
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1.3 TGFβ SIGNALING PATHWAY 
TGFβ is the prototypic member of a large superfamily of evolutionary conserved secreted 
cytokines, which include TGFβs, activins, inhibins, bone morphogenetic proteins (BMPs), 
and growth and differentiation factors (GDFs).  Each of the TGFβ family members have 
crucial roles in multiple processes throughout development and in the maintenance of 
tissue homeostasis in adult life.  Therefore, abnormal signaling by TGFβ family members 
has been implicated in many human disease, including cancer, fibrosis, autoimmune and 
cardiovascular disorders (Blobe, Schiemann et al. 2000, Morikawa, Derynck et al. 2016).  
TGFβ is a potent growth factor for normal epithelial, hematopoetic and immune 
cells, and plays an important function in tissue homeostatis (Roberts and Sporn 1993).  
In humans there are three TGFβ proteins (TGFβ1, TGFβ2, TGFβ3) encoded by separate 
genes (Shi and Massague 2003).  These three human proteins share 75% amino acid 
sequence homology and have demonstrated comparable signaling activities but different 
expression pattern between cells and tissues (Millan, Denhez et al. 1991).  TGFBR1 and 
TGFBR2 receptors contain intracellular serine-threonine kinase domains and on binding 
of the active ligands to their extracellular domains form heteromieric complexes.  Both 
TGFBR1 and TGFBR2 are phosphorylated at tyrosine and serine/threonine residues, 
which enables complex regulatory interactions with a variety of downstream signal 
transduction pathways. 
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Table 1.  Key molecules in the TGFβ signaling pathway 
Molecule category Molecule 
Ligands TGFβ1, TGFβ2, TGFβ3 
Type I receptor  TGFBR1 (ALK5) 
Type II receptor TGFBR2 
Type III receptor TGFBR3 
R-SMADS SMAD2, SMAD3 
Co-SMAD SMAD4 
I-SMAD SMAD6, SMAD7 
TGFβ target genes Collagen, CTGF, αSMA, Periostin 
 
Abbreviation: ALK: activin receptor like kinase; R-SMAD: receptor-specific SMADs; Co-SMAD: 
common mediator SMAD; I-SMAD: inhibitory SMAD 
 
 Active TGFβs ligands bind with high affinity and specificity to the transmembrane 
TGFβ type II receptors (TGFBR2), which activates the TGFβ type I receptor (TGFBR1 or 
ALK5). Activated TGFBR1 initiates canonical SMAD signaling by phosphorylation of 
receptor-associated SMADs (R-SMADs), SMAD2, and SMAD3.  Phosphorylated R-
SMADs form complex with Co-SMAD (SMAD4), which together translocate to the nucleus 
and target gene expression of various biological processes (Feng and Derynck 2005) 
(Figure 2) (Massague and Gomis 2006).  In addition to the canonical signaling described 
above, TGFβs can also signal through non-canonical (non-SMAD) mechanisms, including 
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PI3 kinase, MAPK, RhoA-Rock pathways.  The canonical SMAD pathway is central to the 
growth inhibitory action of TGFβ (Derynck and Zhang 2003, Moustakas and Heldin 2005). 
Figure 2.  TGFβ signaling pathway.  
Signaling by TGFβ through serine/threonine kinase receptors.  Downstream signal transduction 
takes place via SMAD-dependent and SMAD-independent pathways. 
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1.3.1 TGFβ biology 
Mature TGFβ is a covalent 25 KDa homodimer produced after intracellular proteolytic 
cleavage from its propeptide, also known as the latency associated peptide (LAP).   LAP 
component stays bound to the mature TGFβ non-covalently, and the two components 
together form the small latent complex (SLC).  The LAP confers latency to mature TGFβ 
by preventing it from binding to its receptor.  In the endoplasmic reticulum (ER), SLC 
generally becomes disulfide bound to (latent TGFβ binding protein) LTBP proteins via the 
LAP, and together they form the large latent complex (LLC) (Rifkin 2005).  Because 
LTBPs are incorporated into the ECM and TGFβ bound LTBPs are part of LLC, are also 
targeted to the matrix, wherein TGFβ is stored in latent form for future activation (Taipale, 
Miyazono et al. 1994, Isogai, Ono et al. 2003).  Knock-in mice expressing mutant TGFβ1 
which is unable to bind to LTBP exhibit decreased activity of TGFβ, indicating the 
importance of LLC for normal TGFβ signaling (Yoshinaga, Obata et al. 2008).  Various 
molecules in the ECM are able to release TGFβ form its latent complexes and, thus 
activate it, including proteases  (Yu and Stamenkovic 2000), thrombospondin-1 (Schultz-
Cherry and Murphy-Ullrich 1993), reactive oxygen species (ROS) (Barcellos-Hoff and Dix 
1996), and integrins (Munger, Huang et al. 1999).   
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Figure 3.  TGFβ latency, activation and signal transduction. 
ProTGFβ undergoes a series of steps inside the cell through the endoplasmic reticulum and the 
Golgi apparatus to attain a mature TGFβ complex (red) attached to LTBPs and is called large 
latent complex (LLC) .  This mature TGFβ complex is secreted into the ECM wherein the LTBPs 
interact with fibronectin, fibrillin and heparan sulfate proteoglycans. Proteolytic cleavage of latent 
form by ECM components or mechanical stretching leads to release of active TGFβ (green). Cells 
respond to TGFβ through membrane receptors which signal through downstream signaling 
pathways.   
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1.3.2 Extracellular control of TGFβ signaling by elastic fibers 
The ECM provides a repository for a variety of different growth factors (Schultz and 
Wysocki 2009).  Storage and tightly regulated release of TGFβ family of cytokines by the 
ECM components is a good example of multi-faceted interactions between ECM and the 
growth factors (Figure 3).  The general understanding has been that matrix binding of 
latent TGFβ complexes is imperative for proper TGFβ function, and impaired binding to 
the matrix yields a TGFβ deficient state inside the cells.   This hypothesis is supported by 
mutation in Tgfb1 gene which results in decreased matrix association of latent TGFβ and 
yields mice with phenotype associated with decreased TGFβ levels (Yoshinaga, Obata 
et al. 2008).  However, several papers, reported in recent years have shown how 
defective ECM results in enhanced TGFβ signaling instead of the expected decreased 
TGFβ state. 
Recently, a crucial role of elastic ECM has come to fore in regulating TGFβ 
bioavailability in the vascular system.  Defects in the ECM molecules are thought to be 
change the physical properties of the vessel walls and thereby compromise of the 
vasculature.  In addition, several lines of evidence established a link between ECM 
molecules and TGFβ-SMAD signaling at different levels.  Elastic fibers sequester TGFβ 
to play its intracellular role. During normal development or injury, sequestration of TGFβ 
by elastic fibres may be a negative feedback signal indicating that sufficient amounts and 
quality of ECM has been produced.  This link between elastic fibers components and 
TGFβ has been established by reports of loss of function mutations in several ECM 
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proteins (Table 2) showing dysregulated TGFβ signaling and this is discussed in the next 
section.  
Table 2.  Human disorders and animal models associated with elastic fiber 
components and altered TGFβ signaling 
 
Gene Human 
syndrome 
Animal models TGFβ 
signaling 
FBN1 
(Fibrillin-1) 
MFS KO: ruptured aortic aneurysm, impaired 
pulmonary function, die at birth. Het for missense 
mutation (C1039G): aortic aneurysm, 
emphysema.   
⇑ 
FBN2 
(Fibrillin-2) 
Contractural 
arachnodactyly  
KO: bilateral syndactyly  ⇑ 
FBLN4 
(Fibulin-4) 
Autosomal 
recessive cutis 
laxa type 1B 
KO: perinatal lethality, arterial narrowing, aortic 
rupture,  Hypomorphic : tortuous aorta, aortic 
aneurysm 
⇑ 
LTBP1 No disease 
known so far 
KO: persistent truncus arteriosus ⇓ 
LTBP3 No disease 
known so far 
KO: craniofacial malformations, osteosclerosis  ⇓ 
LTBP4 Autosomal 
recessive cutis 
laxa type 1C 
KO: developmental emphysema, aortic tortuosity, 
cardiac hypertrophy, reduced skin thickness  
⇓ 
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1.4  ECM COMPONENTS AND REGULATION OF TGFβ SIGNALING 
1.4.1 LTBPs 
LTBPs are large ECM molecules which are structurally related to fibrillins (FBNs) and are 
ECM components that appear to be involved in the secretion and targeting of TGFβ to 
sites at which it is either stored and/or activated.  Since LTBPs are part of the large latent 
complex (LLC) which is sequestered to the ECM, defective LTBPs should result in 
increased intracellular  TGFβ activity.  However, reduced TGFβ signaling was observed 
in all LTBP mutants studied to date, supporting the notion that LTBPs are not only 
important for the sequestration of TGFβ but also for its activation.  
LTBP-1 deficient mice die shortly after birth from persistent truncus arteriosus and 
interrupted aortic arch, along with cardiac abnormalities like hypoplastic endocardial 
cushions during early development and hyperplastic valves during late valvulogenesis, 
as a result of altered epithelial to mesenchymal transition, a process known to be 
mediated by TGFβ.  The cell populations of the heart in these mice show decreased TGFβ 
signaling illustrated by reduced pSmad2 staining and a decrease in the expression of 
TGFβ responsive genes like connective tissue growth factor (CTGF) and periostin 
(Todorovic, Frendewey et al. 2007, Todorovic, Finnegan et al. 2011).  Similarly, mice 
deficient of LTBP3 show phenotype of bone abnormalities and defective septation of the 
terminal pulmonary air sacs, phenotypes consistent with loss of TGFβ signaling (Dabovic, 
Chen et al. 2002, Colarossi, Chen et al. 2005).  Unlike LTBP-1 and LTBP-3, LTBP-4 has 
multiple functions, both as regulator of TGFβ and also a promoter of elastic fiber 
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assembly. LTBP4-/- mice display developmental emphysema, cardiac hypertrophy and 
colorectral proplapse with diminished ECM deposition of TGFβ1 and decreased p-Smad2 
in lungs and colon (Sterner-Kock, Thorey et al. 2002). In addition to binding TGFβ1, 
LTBP4 facilitates TGFβ signaling by binding TGFBR2 and stabilizing the TGFBR receptor 
complex for sustained signaling. In the absence of LTBP4 the TGFBR receptor complex 
undergoes ligand-mediated endocytosis and lysosomal degradation (Su, Huang et al. 
2015).   Similar studies have not been performed to test if LTBP1 and LTBP3 play role in  
stabilizing TGFBR complex.   
1.4.2 Fibrillins 
Fibrillins are major constituents of microfibrils and bind LTBPs (Isogai, Ono et al. 2003). 
Therefore, impairment of microfibril organization due to mutations in fibrillin-1 should 
affect the sequestration of LLC into the ECM and alter TGFβ signaling.  Indeed, mutations 
in fibrillin-1 causes Marfan syndrome (MFS) a systemic connective disorder primarily 
associated with cardiovascular manifestations in which disruption of the microfibrils leads 
to decreased incorporation of the LTBP in the ECM but increased TGFβ signaling both in 
patients and in fibrillin-1 deficient mice (Dietz, Cutting et al. 1991, Zilberberg, Todorovic 
et al. 2012).  Consistent with this observation, several phenotypes of MFS, including aortic 
dilation and dissection, hypertrophic mitral valves and developmental emphysema, are 
reversed in fibrillin-1 mutant mice by the administration of TGFβ neutralizing antibody 
(Neptune, Frischmeyer et al. 2003, Ng, Cheng et al. 2004).  These observations are 
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consistent with a function of fibrillin-1 in TGFβ signaling sequestration but not in TGFβ 
activation.  
1.4.3 Fibulins 
Fibulins comprise a group of eight proteins, among which FBLN -3, -4, -5 play important 
roles in elastic fiber formation and maintenance.  Thus, deficiency in these proteins results 
in impaired elastogenesis (Nakamura, Lozano et al. 2002, McLaughlin, Chen et al. 2006, 
McLaughlin, Bakall et al. 2007, Horiguchi, Inoue et al. 2009), but so far none are known 
to interact with components of TGFβ complex (latent or active) or to play any role in TGFβ 
sequestration. Nevertheless, evidence for increased canonical TGFβ signaling has been 
found in both humans and mice deficient in fibulin-4.  Fbln4 deficient mice show enhanced 
TGFβ signaling by enhanced p-Smad2 levels in the aortic tissues and increased TGFβ2 
levels in blood plasma (Hanada, Vermeij et al. 2007, Ramnath, Hawinkels et al. 2015).  
In another study, smooth muscle-specific conditional knockouts of Fbln4 showed 
enhanced TGFβ signaling through non-canonical pathway, as indicated by increased 
Erk1/2 phosphorylation (Huang, Davis et al. 2010). 
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1.4.4  Role of TGFβ in vascular development 
Blood vessels form by a combination of two processes known as vasculogenesis and 
angiogenesis, both of which lead to formation of tubes lined by endothelial cells (Adams 
and Alitalo 2007).  Vasculogenesis refers to formation of new vessels from a mass of 
proliferating cells to form a primary capillary plexus.  Angiogenesis refers to sprouting of 
new capillary networks from pre-existing vessels (Risau 1997).  Both of these processes 
are regulated by growth factors in a highly coordinated manner during embryo 
development.  The critical role of TGFβ family members in vascular development is 
underscored by the observations that nearly all knock-out mice for TGFβ receptors, 
ligands and intracellular components lead to death during midgestation due to heart 
defects and lack of circulation and mutations in the genes encoding TGFβ pathway 
components are linked to increasing number of human pathologies with vascular 
dysfunction as shown in Table 3.  Mice with null mutation in Tgfb3 result in neonatal lethal 
lung dysplasia with intrapulmonary vascular dysplasia as well as cleft palate (Kaartinen, 
Voncken et al. 1995).  Null mutation in Tgfb2 results in early embryonic lethality owing to 
cardiac defects as well as defects in pulmonary lobation (Bartram, Molin et al. 2001).  Null 
mutation in Tgfb1 gene results in lethal postnatal pulmonary inflammation (Shull, Ormsby 
et al. 1992).  The embryos lacking receptors TGFBR1 (ALK5) and TGFBR2 die during 
mid-gestation due to impaired vascular development, exhibiting hyper-dilated and leaky 
vessels.  The primary target cell for the TGFβ is the endothelial cell (EC) but is also is 
important for proper differentiation and function of SMCs and pericytes (Goumans and 
Mummery 2000). 
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Table 3.  Human syndromes and animal models associated with dysregulation in 
TGFβ signaling components 
Gene Human syndrome & 
Symptoms 
Animal models 
TGFB1 Camurati-Engelmann disease 
– bone dysplasia, muscular 
weakness, limb pain, 
fatigablity.  
KO: embryonic lethal with vascular 
defects or postnatal lethality from 
autoimmune disease (phenotype is 
modifier dependent) 
TGFB2 Familial thoracic aortic 
aneurysms and dissections   
KO: aortic arch defects, cardiac septal 
defects, perinatal lethality 
TGFB3 Syndrome with low muscle 
mass, growth retardation, and 
clinical features like MFS  
KO: cleft palate, delayed lung 
maturation, die shortly after birth 
TGFBR1/ALK5 Loeys-Dietz syndrome – 
aortic aneuryms and 
tortuosity, hypertelorism and 
cleft platate 
KO: embryonic lethal, angiogenesis 
defects.  
TGFBR2  Loeys-Dietz syndrome  KO: embryonic lethal, vascular defects 
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1.4.5 Interplay between elastic fibers and TGFβ signaling 
The interplay between multiple ECM components, latent TGFβ complexes and TGFβ 
activators determine the levels of active TGFβ.   Some of these interactions have been 
recognized through studies of rare genetic disorders affecting connective tissues, such 
as in MFS, Loeys-Dietz syndrome (LDS) and cutis laxa. During normal development or 
injury, sequestration of TGFβ by elastic fibers can be thought of as a negative feedback 
signal indicating that sufficient amounts and quality of ECM has been produced.  Loss of 
function mutations in elastic fiber genes playing role in TGFβ sequestration like FBN1 
result in elevated TGFβ signaling (Kaartinen and Warburton 2003, Dabovic, Chen et al. 
2009).  
Conversely, TGFβs can up-regulate the expression of many genes necessary for 
the production of elastic fibers including fibronectin (Ignotz, Endo et al. 1987), LTBPs 
(Weikkolainen, Keski-Oja et al. 2003), ELN (Kucich, Rosenbloom et al. 1997), LOXs (Kim, 
Lee et al. 2008), and FBLN5 (Kuang, Joyce-Brady et al. 2006).  This regulation by TGFβs 
occurs at the transcriptional or posttranscriptional level depending on the gene.  In an 
example of post-transcriptional regulation, both ELN and FBN1 are in part suppressed by 
miR29 family of micro-RNAs  by binding to the 3’-untranslated regions of both RNAs  (van 
Rooij, Sutherland et al. 2008). The expression of miR29 is inhibited by TGFβ, thus 
relieving the repression of the FBN1 and ELN. 
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1.4.6 Therapeutic targeting of TGFβ signaling pathway 
As TGFβ affects wide variety of biological processess, blockage of TGFβ and its signaling 
pathway provides multiple therapeutic opportunities.  There are 4 major types of TGFβ 
inhibitors use for limiting cancer progression and in some instances vascular 
abnormalities in humans and animal models which can be classified as 1.) Ligand traps, 
2.) antisense oligonucleotide, 3.) small molecule kinase inhibitors, and 4.) peptide 
aptamers (Figure 4) (de Larco and Todaro 1978, Moses, Branum et al. 1981).    
Ligand traps include use of anti-ligand neutralizing antibody raised against 
individual ligands or against all 3 TGFβ ligands by designing appropriate epitope or 
soluble receptor proteins that have the ability to compete with TGFβ receptors.  Some of 
the humanized pan-TGFβ monoclonal antibodies are developed by Genzyme for patients 
including Lerdelimumab (Mead, Wong et al. 2003), Metelimumab (Cordeiro, Gay et al. 
1999) , and GC-1008 (Fresoliumumab) (Morris, Tan et al. 2014).   TGFβ monoclonal 
antibody, 1D11,  developed by Sanofi, which is a pan-neutralizing anti-mouse TGFβ 
antibody has been shown to bind to all three TGFβ isoforms and reduce the lung cancer 
metastatis (Nam, Terabe et al. 2008).  Antisense oligonucleotides (ASOs) can also be 
used to reduce bioavailability of TGFβ ligands by blocking TGFβ synthesis post-
transcriptionally.  
ASOs are single-stranded nucleotide molecules, which hybridize to target mRNA, 
and thereby inhibiting its translation and/or promoting its synthesis by mRNA degradation 
of the blocked mRNA (Bennett and Swayze 2010). One of the TGFβ2 targeting ASO is 
AP12009 (Trabedersen) (Hau, Jachimczak et al. 2007) .  However, oligonucleotides have 
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some limitations like RNA binding affinity, and possible non-specific/off target effects and 
issues with cellular uptake. 
Whereas ligands traps and ASOs limit the biosynthesis of the TGFβ ligands, they 
fail to block receptor signaling.   This is where a class of kinase receptor kinase blocking 
inhibitors have been developed and used to block TGFβ signaling. Glaxosmithkline 
developed a small molecule inhibitor, SB-431542, which specifically targets TGFβRI and 
is now widely used in basic research for in in vitro studies (Laping, Grygielko et al. 2002). 
LY364937, another TGFβRI/ALK5 inhibitor has shown to be reduce early lung and bone 
metastases in nude mice (Bandyopadhyay, Agyin et al. 2006).    
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Figure 4.  Inhibition of TGFβ signaling pathway.  
The TGFβ is often elevated in human tumors and vasculature.  This has led to development of 
range of anti-TGFβ drugs.  The four major classes of TGFβ inhibitors include ligand traps, 
antisense oligonucleotides, peptide aptamers and kinase inhibitors  
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1.5 FIBULIN-4 
Fibulin-4, also known as EFEMP2 (epidermal growth factor domain containing fibulin-like 
extracellular matrix protein 2) or MBP1 (mutant p53 binding protein 1), is a 54 KDa, 433 
amino acid ECM glycoprotein that is rich in negatively charged amino acids, giving it 
slightly acidic properties (Gallagher, Greene et al. 2001).  It is one of the eight members 
in the fibulin family of ECM glycoproteins involved in ECM organization and function. 
Throughout this thesis I will use fibulin-4 (FBLN4 for human and Fbln4 for zebrafish) 
instead of EFEMP2 to emphasize the structural and functional similarities among the 
members of the fibulin gene family. FBLN4 is highly expressed in the medial layers of 
arteries and veins and in heart valves, and moderate level of expression is seen in skeletal 
muscle, placenta, kidneys and pancreas, and low levels in lungs and brain.  FBLN4 is 
also expressed in adult human fibroblasts and articular chondrocytes (Chen, Zhang et al. 
2009).   Like all the other members of fibulin family of proteins, fibulin-4 contains a 
characteric N-terminal domain, an array of calcium-binding epidermal growth factor (EGF) 
like domains, the first with an additional 28 amino acid insert, and a characteristic fibulin 
C-terminal (FC) domain.  The N-terminus contains a signal peptide sequence, which is 
required for FBLN4 to be secreted into the extracellular space and also an EGF-like 
adjoining domain.  The gene encoding fibulin-4 has been mapped to human chromosome 
11q13, and the protein is encoded by 11 exons (Katsanis, Venable et al. 2000).  Fbln4 
was first identified as an N-terminally truncated protein lacking a signal peptide and 
interacting with the intracellular mutant tumour suppressor protein p53 (Gallagher et al., 
1999).  However, these studies have not been replicated since and all currently annotated 
FBLN4 transcripts have a signal peptide. 
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1.6 FUNCTIONS OF FIBULIN-4 
Several studies have shown that fibulin-4 is essential for elastogenesis, and for normal 
composition and functions of tissues abundant in elastic fibers, such as heart, blood 
vessels, and lungs.  Recently, fibulin-4 has been shown to be important in other 
processes, such as smooth muscle cell differentiation, control of TGFβ bioavailability and 
bone development (Horiguchi, Inoue et al. 2009, Renard, Holm et al. 2010, Erickson, 
Opitz et al. 2012).   In the ECM fibulin-4 is known to be binding to tropoelastin and LOX, 
two components that play crucial roles in the elastic fiber assembly (Choudhury, 
McGovern et al. 2009, Horiguchi, Inoue et al. 2009).   
1.6.1 Fibulin-4 is essential for elastic fiber assembly 
The importance of fibulin-4 for normal development of tissues rich in elastic fibers was 
first demonstrated by a knockout mouse model studied by McLaughlin et al.  Mice lacking 
fibulin-4 developed lethal lung and vascular defects, such as emphysema, arterial 
tortuosity, aneurysm and hemorrhages, resulting in prenatal death. (McLaughlin, Chen et 
al. 2006).  Histological examination of aorta, lung and skin of these mice showed severely 
fragmented elastic fibers.  These characteristics phenotypes and elastic fiber disruption 
were later found associated with FBLN4 mutations in human patients (Hucthagowder, 
Sausgruber et al. 2006, Hoyer, Kraus et al. 2009, Renard, Holm et al. 2010, Sawyer, 
Dicke et al. 2013).   
In the fibulin-4 knockout mice, elastin aggregates were observed forming electron-
dense rod-like structures instead of solid, continuous elastic lamellae suggesting 
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improper elastin crosslinking.  Indeed, a 94% drop in the levels of desmosine was 
observed, which is a crosslink product only found in mature elastin.  However, at the gene 
expression level, the synthesis of neither tropoelastin nor LOX were altered in fibulin-4 
mutant mice.  In summary, fibulin-4 facilitates elastin assembly and crosslinking.   
1.6.2 Fibulin-4 regulates the differentiation and function of aortic smooth muscle 
cells 
Although mouse models of elastin, fibulin-5 and fibulin-4 deficiency all exhibit disrupted 
elastic fibers and similar vascular and lung abnormalities, only absence of fibulin-4 causes 
lethal ruptured aortic aneurysms.  Therefore, it is believed that apart from its role in elastic 
fiber assembly, fibulin-4 must have another function in the aortic wall.  Huang et al (2010) 
developed a smooth muscle specific (SMC) fibulin-4 deficient mice which exhibited lethal 
aortic aneurysms and the analysis of its aortic smooth muscle cells revealed several 
abnormalities.  The SMCs showed increased proliferation, decreased differentiation, 
degenerative changes and reduction in smooth muscle contractile proteins (Huang, Davis 
et al. 2010).  As a result, the function of SMCs was severely impaired, affecting the 
stability of the aortic wall. The aorta of these deficient mice showed increased pERK1/2 
signaling.  In an another study by Ramnath et al (2015) isolated SMCs from fibulin-4 
deficient mice showed reduced growth and upregulated TGFβ signaling by increased 
SMAD2 phosphorylation.  The reduced growth of SMCs in these mice could be reversed 
by treatment with TGFβ neutralizing antibody (Ramnath, Hawinkels et al. 2015).   These 
findings suggest that fibulin-4 has an indispensable role in the development of the 
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vascular system through its role both in elastic fiber formation and in differentiation and 
function of aortic SMCs. 
1.6.3 Fibulin-4 and control of TGFβ bioavailability 
Patients suffering from fibulin-4-associated cutis laxa and mice lacking fibulin-4 exhibit 
increased TGFβ signaling (Hanada, Vermeij et al. 2007, Renard, Holm et al. 2010).  TGFβ 
signaling is upregulated in aortas of adult hypomorphic mice (FBLN4R/R) mice and 
postnatal treatment with losartan, an angiotensin (Ang) II type 1 receptor antagonist  and 
an indirect inhibitor of TGFβ signaling improves lifespan of FBLN4R/R mice, however does 
not affect aortic vessel wall structure. Prenatal treatment of these mice with losartan 
prevents elastic fiber fragmentation in the aorta, strongly indicating that altered TGFβ is 
associated with disturbed elastic fiber structure which is consistent with the view that 
elasin is required during late prenatal to early post natal periods of development  (Moltzer, 
te Riet et al. 2011). TGFβ pathway which is essential for controlling cell proliferation and 
differentiation, and its perturbation has also been implicated in numerous other 
cardiovascular diseases, including Marfan syndrome and LDS as mentioned earlier 
(Neptune et al., 2003) (Loeys, Chen et al. 2005).  The reasons for dysregulated TGFβ 
signaling are not known but one possible explanation can be fragmentation of elastic 
fibers in absence of fibulin-4 may be leading to impaired sequestration of TGFβ. Recently 
it has been shown that there is a direct functional and biochemical interaction between 
LTBP-4 long form and fibulin-4 (Bultmann-Mellin, Essers et al. 2016) providing an 
explanation for altered TGFβ sequestration in fibulin-4 deficient tisues.  In summary, 
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increased TGFβ signaling been suggested by multiple lines of evidence as one of the 
contributing pathological mechanisms leading to the phenotype observed in patients 
suffering from cutis laxa caused by mutations in fibulin-4.  
1.6.4 Fibulin-4 deficiency and mutations 
Biallelic loss of function mutations in the FBLN4 gene cause autosomal recessive cutis 
laxa 1B (ARCL1B) which is a rare disease with manifestations including sagging skin, 
arterial tortuosity, aortic aneurysms, pulmonary hypertension, developmental 
emphysema, bone fragility, arachondactlyly, joint laxity and diaphragmatic and inguinal 
hernias.  The first mutation in the FBLN4 gene was reported in a 2 yr old girl, a recessive 
missense mutation (p.E57K) (Hucthagowder, Sausgruber et al. 2006).  Since then a total 
of 35 patients have been reported worldwide with ARCL1B, and 26 of them died either at 
birth or early childhood (Dasouki, Markova et al. 2007, Hoyer, Kraus et al. 2009, Renard, 
Holm et al. 2010, Al-Hassnan, Almesned et al. 2012, Erickson, Opitz et al. 2012, Iascone, 
Sana et al. 2012, Kappanayil, Nampoothiri et al. 2012, Sawyer, Dicke et al. 2013, Hebson, 
Coleman et al. 2014).  The 12 pathogenic mutations include 9 missense and 3 frameshift 
mutations which are uniformly distributed within the FBLN4 gene (Figure 5).  Parents, 
who are heterozygous carriers of disease-causing FBLN4 mutations are asymptomatic 
and commonly consanguineous.  Reports of FBLN4 mutations resulting in disease are 
rare, and due to frequent neonatal lethality, ARCL1B is likely to be underdiagnosed. 
Diagnosis of autosomal recessive cutis laxa caused by fibulin-4 mutations can be 
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challenging due to large phenotypic overlap with other subtypes of cutis laxa and arterial 
tortuosity syndromes, and due to clinical heterogeneity shown by patients.  
Figure 5.  Fibulin-4 mutations in ARCL1B.   
A signal peptide at the N-terminus (orange), EGF-like adjoining domain (purple), followed by a 
modified cbEGF-like domain (green) with a 28 amino acid insert (yellow), five cbEGF-like domains 
(blue) and the C-terminal FC domain (red hexagon).  Tie lines indicate the locations of ARCL1B 
mutations identified to date. 
 
1.6.5 ZEBRAFISH AS A MODEL FOR STUDIES ON FBLN4 
The zebrafish has become a central model system to investigate vertebrate development 
by both forward and reverse genetics (Lawson and Wolfe 2011).  Early foundational 
studies utilized zebrafish in large-scale forward genetic screens, based simply on 
observing embryonic morphology resulted  discovery of many genes which play role in 
different aspects of embryonic development including gastrulation, cardiovascular 
morphogenesis, and hematopoiesis (Hammerschmidt, Pelegri et al. 1996, Ransom, 
Haffter et al. 1996, Stainier, Fouquet et al. 1996, Goessling and North 2014).  Zebrafish 
presents advantages to its users by having a rapid external development, with 
gastrulation starting by 6 hpf, heart beating by 24 hpf and circulation through head and 
tail of the embryo by 30 hpf (Isogai, Horiguchi et al. 2001). Zebrafish adults lay large 
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clutch sizes of transparent embryos which facilitate mapping of causative mutant genes 
during embryogenesis (Lawson and Wolfe 2011). Zebrafish is amenable to genetic 
manipulation and permanent knockout lines are generated using CRISPR/Cas9 or 
TALEN technology, while transient gene knockdown studies are performed using 
antisense oligonucleotide (Bedell, Wang et al. 2012, Hruscha, Krawitz et al. 2013).  In 
addition to genetic studies, zebrafish also supports pharmacological approaches.  
Addition of previously characterized small molecules to fish water allows researchers to 
manipulate specific biochemical pathways of interest, and also allows for identification of 
novel small molecules that perturb particular signaling pathways or developmental 
processes by use of chemical screens  (Goessling and North 2014).  
1.6.6 Zebrafish Fibulin-4a 
In addition to its role in elastic fiber assembly during late fetal periods, zebrafish Fbln4a 
is required for gastrulation process during embryogenesis.  It facilitates cell migration for 
the the anterior convergent movements of the prechordal plate progenitors downstream 
of Wnt/βcaternin/Stat3 pathway.  Knockdown of Stat3 and Fbln4a separately showed 
abnormal anterior migration during zebrafish gastrulation, resulting in a mispositioned and 
shortened anterior-posterior (AP) axis (Zhang, Yin et al. 2014).  However, cell 
specification of gastrulation progenitors was not affected by knockdown of fbln4a.  In in 
vitro and in vivo experiments, Fbln4a protein was secreted into the ECM and promoted 
for formation of fibronectin (FN) and laminin (LM) matrices.  Increase or decrease in wild 
type fbln4a expression or overexpression of mutant fbln4a was able to disrupt FN and LM 
matrix identifying a previously unrecognized function of Fbln4a.   
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1.7 DISSERTATION AIMS 
Fibulin-4 is an ECM glycoprotein that is essential for elastogenesis and hence for  
appropriate elastic recoil functions of elastic fiber-rich tissues such as aorta, elastic 
arteries, lungs and skin.  Mouse studies by various research groups have extensively 
focused on understanding postnatal role of the FBLN4 and have shown its role in elastic 
fiber assembly and integrity of aortic structure. Moreover, previous human and mouse 
studies have shown abnormal transforming growth factor-beta (TGFβ) signaling in FBLN4 
mutant tissues.  
However, not much is known about the embryonic role of fibulin-4 and the 
pathological molecular mechanisms that underlie the developmental disease caused by 
loss of fibulin-4.  This is where zebrafish model proves advantageous as the transparent 
embryo develops rapidly, outside of mother’s body, and has fully developed organs (or 
counterparts to mammalian organs) including a functioning cardiovascular system within 
2 days post fertilization. A recent zebrafish transient knockdown study showed that 
Fbln4a is required for the organization of the extracellular matrix (ECM) and the 
convergent extension movements of the prechordal plate progenitors during gastrulation 
(Zhang, Yin et al. 2014), however, it remains unclear how these developmental changes 
are related to phenotypes observed in patients with permanent FBLN4 mutations, and 
what signaling pathways are activated as a consequence of Fbln4a deficiency.  
Based on the above discussed published knowledge, I hypothesized that Fbln4a 
deficiency alters the differentiation of cardiac and vascular progenitors through the 
dysregulation of TGFβ signaling at early embryonic stages to which contributes to the 
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cardiovascular malformations observed after organogenesis. To test this hypothesis I 
pursued 3 specific aims: 
Aim 1.  Characterize the gene expression pattern of fbln4a during early 
development to identify the tissues wherein fbln4a mRNA and protein are expressed.  
Aim 2.  Perform loss of function studies for fbln4a using a retroviral mutant and 
also by generating and validating transient knockdown reagents of fbln4a.  Compare the 
loss of function effects between germline mutant and transient knockdown with a focus 
on cardiovascular development.  
Aim 3.   Test if altered TGFβ signaling mediates the cardiovascular lesions in 
Fbln4a deficient embryos using small molecule inhibitors, and identify the critical period 
of TGFβ action.  
 
According to National Institutes Health Office of Rare disease research estimated 30 
million people living in the United States have some type of rare disease of which there 
are more than 7000 types.  More than 80% of rare diseases are genetic and can be life 
threating and 30% of rare disease patients die before the age 5 deeply impacting patients 
and their families with physical and mental distress (Moisan, Ricketts et al. 1999, 
Bavisetty, Grody et al. 2013).   Since majority of rare genetic diseases are monogenic 
and are transmitted from parents to offspring; it makes them excellent targets for study in 
animal models like mouse and zebrafish.  Animal models of human disease lay foundation 
for drug discovery as they allow for identification of novel pharmacologics while 
connecting gene function with specific pathogenesis.  Several novel small molecules with 
potential to treat human pathologies have been discovered using high throughput 
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zebrafish drug screens and since then have entered into clinical trials (Cutler, Multani et 
al. 2013, Zon 2014, Li, Lahvic et al. 2015).   
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2.0  MATERIALS AND METHODS 
2.1 ZEBRAFISH MAINTENANCE AND CARE 
Adult zebrafish (Danio rerio) were maintained according to standard husbandry protocols 
and experiments were performed in accordance with NIH guidelines.  Embryos were 
grown at 28.5°C in 30% Danieau [17mM NaCl, 2mM KCl, 0.12mM MgSO4, 1.8 mM 
Ca(NO3)2, 1.5mM HEPES]. For imaging, embryo medium was supplemented with 
0.0003% phenylthiourea (Sigma, St. Louis, MO, USA) at ~ 24 hours post-fertilization (hpf) 
to prevent melanin synthesis.  Wildtype AB* zebrafish embryos were used for injection 
purposes.  Embryos were staged following published guidelines (Kimmel, Ballard et al. 
1995) 
2.2 PROTEIN SEQUENCE ANALYSIS  
Amino acid sequences of human and zebrafish FBLN4 were obtained from the GenBank 
database.  The accession code for human FBLN4 - NP058634, zebrafish Fbln4a - 
NP001008587 and Fbln4b - NP001153830. Protein sequence alignment was performed 
using multiple sequence alignment feature of CLC Main Workbench 6.9.1.    
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2.3 MORPHOLINO-MEDIATED KNOCKDOWN 
Antisense morpholinos (MO) were purchased from Gene Tools, Philomath, Oregon, USA.  
Splice blocking MOs were designed following the recommendations of the manufacturer 
to target the exon 3/intron 3 junction of fbln4a using (MO-1: 5’-
TGAAGCGTGTTTTACCTTTGCAGTG -3’). To target fbln4b gene we used (MO-2: 5’-
CACTCATTTATGTCTGCGTACAATA-3’) against the exon 4/intron 4 junction. The 
morpholinos were diluted in distilled water and pressure-injected into the yolk cells of 1- 
to 2-cell stage embryos using Eppendorf FemtoJet Micromanipulator 5171.  Phenol red 
(1x) (Sigma) was co-injected as a dye tracer.  MO concentrations were determined 
spectrophotometrically and 5 nl was injected into embryos at increasing doses (1-10ng) 
to determine optimal concentrations.  The optimal dose for both MO-1 and MO-2 both 
was selected as 5ng based on phenotypic effect.   The control morpholino (5’-
CCTCTTACCTCAGTTACAATTTATA-3’) targeting human beta-globin gene (GenBank 
accession number - AH001475.2) was injected as the same concentration as the 
experimental morpholino (5ng) for each experiment. 
2.4 RNA FOR MICRO-INJECTION 
A full-length 1.4kb fbln4a c-DNA was cloned into pCRII-TOPO plasmid vector.   The vector 
containing fbln4a cDNA cassette was double digested with HindIII and EcoRI restriction 
enzyme (New England Biolabs) and the cassette was gel eluted and ligated into pOX 
oocyte expression vector for making fbln4a mRNA. For in vitro transcription, 10µg of 
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fbln4a-pOX plasmid DNA was digested with EcoRI for linearization and finally 1µg was 
used as template for T3 in vitro transcription using mMessage Kit (Invitrogen).  mCherry 
mRNA provided by Dr. Michael Tsang (Univeristy of Pittsburgh) was used as  control 
RNA. 1 μl of RNA was micro-injected into the cytoplasm of 1 cell stage embryos.  
2.5 DNA ISOLATION, PCR AND DNA SEQUENCING  
For genotyping, genomic DNA was isolated from whole embryos or adult tail biopsies 
using DNeasy Blood and Tissue Kit (QIAGEN) and 30ng of DNA for used for each PCR 
reaction. Validation of retroviral mutant was performed by designing a genotype assay to 
amplify intronic and exonic regions at the site of retroviral insertion in fbln4a gene.     
Primers were designed using Design primer feature of CLC Main workbench version 6 
(Table 4). 
2.6 HEART RATE MEASUREMENT  
Embryos were kept in individual dishes and individually removed from the 28°C incubator 
immediately prior to measurement to minimize the effect of temperature on heart rate.  
Heart rates were measure directly by observing the embryos under a stereomicroscope 
and counting heart beats for 1 min. 
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2.7 RNA ISOLATION AND RT-PCR  
Total RNA isolation, total RNA was extracted using 500μl TRIzol reagent (Invitrogen) from 
a clutch of 30-40 embryos at different developmental stages.  The samples were 
homogenized using a plastic homogenizer pestle (USA Scientific).  TRIzol separates the 
lysates, on addition of phase separator bromochloroporpane (BCP) into 3 phases: a lower 
red organic phase, an interphase containing DNA, and a colorless, upper aqueous phase 
with RNA. After 10min storage at room temperature, the suspension was centrifuged at 
10,000g for 15 min at 4°C.   The upper phase was transferred into a new tube and mixed 
with RNase-free 70% ethanol.  The samples were next transferred to RNeasy Minelute 
spin column as part of the RNA Mini Kit (QIAGEN). Next the samples washed twice with 
500μl 80% ethanol a couple of times.  Finally, RNA was eluted in 15 μl RNase-free water.  
The concentration of the RNA was measured by UV spectrophotometry using a Nanodrop 
2000 instrument (Thermo Fisher Scientific).  RT-PCR analysis do determine efficacy of 
splice morpholinos was carried out on total RNA isolated from zebrafish embryos or adult 
tail biopsies using Trizol (Invitrogen), and 1μg of RNA was reverse-transcribed with 
Superscript IV First Strand Synthesis System (Thermo Fisher Scientific) to produce 
complementary DNA (cDNA), following the manufactures instructions.  To each RNA 
sample (1μl), random hexamers (1μl, 50ng/μl), dNTPs, and DEPC-treated water (up to 
10μl) were added before a 5 min incubation at 65°C.  Before PCR, 10x RT Buffer (2 μl), 
MgCl2 (4μl, 25nM), dithiothreitol (DTT, 2μl, 0.1M), RNase OUT (1μl, 40U/μl), SuperScript 
III Reverse transcriptase (200U/μl; 1μl) were added to the mix.  After incubation for 10min 
at 25°C, 50 min at 50°C and 5 min at 85°C, the reactions were chilled on the ice, briefly 
centrifuged, 1μl RNase H was added to each sample and the reactions were incubated 
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at 37 °C for 20 min.  The cDNA reactions were stored in -20°C and 0.5 μl of this reaction 
was used in polymerase chain reaction (PCR).  For direct visualization of amplification 
products, cDNA was amplified using standard PCR conditions and appropriate primer 
pairs of different exons (Table 4).  
2.8 WHOLE MOUNT IMMUNOSTAINING AND WGA STAINING 
Whole-mount embryos were fixed in 4% paraformaldehyde (PFA) at 4°C overnight.  After 
fixation, the embryos were washed 2 times 5 min each in PBS containing 0.1% Triton X-
100, followed by 1h wash in PBS containing 0.5% Triton X-100 at room temperature.  
After the wash, the embryos were blocked for 3 h at room temperature in blocking buffer 
containing PBS in 1% DMSO, 1% Triton-X 100, 0.2% BSA and 5% normal donkey serum. 
Embryos were incubated overnight at 4°C in a 1:250 dilution of Fbln4a primary antibody, 
and washed 4-6 times 30 min each in PBS containing 0.1% Triton X-100 (PBST). The 
embryos were again blocked in blocking buffer for 1h and followed by 3h incubation with 
Alexa 568 anti rabbit IgG secondary antibody at 1:250 dilution. Whole embryos were 
washed 4 times 15 min each in PBST at room temperature.  For wheat germ agglutinin 
(WGA) staining embryos were washed 2 times with PBST containing Rhodamine labeled-
WGA (Vector Laboratories, Catalog number - RL1022) at 1: 1000 dilution for 10 min each.  
Next, embryos were washed 2 times with PBST 10 min each and placed in PBS and 
imaged using an Olympus BX51 microscope and DP71 camera. 
 41 
Table 4. Primers used for morpholino and genotyping validation 
RT-PCR for 
morpholino 
resulted 
exon 
splicing 
Primer and Sequence Tm,  
Extension 
time  
fbln4a c-DNA (forward fbln4a:exon1)  5’ CTCAGAAAGAGATCCACTG 
3’ 
(reverse fbln4a:exon4) 5’ CAGGCTTCAGTGATTGTC 3’ 
50°C, 30 sec  
fbln4b c-DNA (forward fbln4b:exon2) 5’ TGTGTATGTGACAGTGTG 3’ 
(reverse fbln4b:exon6) 5’ AAGAGAAAGATCCTGGCA 3’ 
50°C, 30 sec   
actin c-DNA (forward actin) 5’ AATGAGCGTTTCCGTTGC 3’ 
(reverse actin ) 5’ GGACAGGGAGGCCAAGAT 3’ 
50°C, 30 sec   
Genotyping 
of mutant 
line 
  
        fbln4a (forward fbln4a:intron1) 5’ 
GATATTTAGGAACCGTGTGA 3’ 
(reverse fbln4a:exon3) 5’ 
CTTTGCAGTGCTGAGTCTGTG 3’ 
(reverse retrovirus) 5’ TCGGACAGACACAGATAA 3’ 
50°C, 60 sec 
 
RT-PCR for 
mutant line 
  
fbln4a c-DNA (forward fbln4a:exon1) 5’ CTCAGAAAGAGATCCACTG 
3’ 
(reverse fbln4a:exon3) 5’ 
CTTTGCAGTGCTGAGTCTGTG 3’ 
(forward fbln4a:exon4) 5’  GACAATCACTGAAGCCTG 3’ 
(reverse fbln4a:exon6) 5’  GACATTAACACAGCGATG 3’ 
(forward fbln4a:exon8) 5’  CTACCTGTGCCAATATCA 3’ 
(reverse fbln4a:exon10) 5’ TCCATTGTCATCTCCAGA 3’ 
50°C, 30 sec 
 
50°C, 30 sec 
 
50°C, 30 sec 
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2.9 PROTEIN EXTRACTION AND IMMUNOBLOTTING 
Embryos were dechorionated by pronase and deyolked in PBS supplemented with a 
protease inhibitor cocktail (P1860, Sigma) by vigorous pipetting followed by a short 
centrifugation step.  Protein lysate was extracted using a lysis buffer containing 20 mM 
Tris/Cl pH 7.5, 150mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% TritonX-100 and protease 
inhibitor cocktail (Sigma).  Embryos were homogenized using a pestle homogenizer for 
30-45 seconds and lysate was incubated on ice for 5 min. Supernatants were clarified by 
centrifugation at 14000rpm for 5 min in a microcentrifuge at 4°C.  Protein concentration 
was measured using Bradford assay and samples were stored in -80°C.  A total of 15µg 
of protein was loaded on a 4-15% SDS-PAGE gradient gel.  Before loading samples were 
incubated at 95°C for 5 min in Laemmli Sample buffer (4x, Bio-Rad) and supplemented 
with 5% β-mercaptoethanol.  The SDS-PAGE gel was subjected to electrophoresis at 
100V for 75 min to 90 min. For transfer, the gel was positioned between packing pads, 
filter papers and polyvinylidene difluoride (PVDF) membrane and then placed into a Bio-
Rad Mini Trans-Blot Electrophoretic Transfer Cell for 120 min at 80 V on ice.  Nonspecific 
binding sites on the membrane were blocked by incubation in Odyssey Blocking Buffer 
(Li-cor) for 1 h. Antibodies were diluted in Odyssey Blocking Buffer, containing 0.2% 
Tween 20 (Fisher). The incubation with primary antibodies was overnight at 4°C.  The 
incubation with secondary antibodies was for 1h at room temperature.  Blots were 
scanned using Li-cor Odyssey CLx Infrared imaging system, and band intensity was 
quantified and normalized using the Image Studio software. Primary antibodies used were 
anti-Fbln4a (anti-rabbit antiserum raised against the unique peptide sequence in the 
1stcalcium binding EGF domain) (1:1000), anti-Actin (C-11) (sc-1615, Santa Cruz) 
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(1:3000).  Secondary antibody used for immunoblotting were IRDye 800CW donkey anti-
rabbit IgG (H+L) (Li-cor) (1:10000), and IRDye 680LT donkey anti goat (H+L) (Li-cor) 
(1:10000).  
2.10 IN SITU  HYBRIDIZATION 
Embryos were collected at different developmental stages: 30% epiboly, shield, 75% 
epiboly, tailbud, 2 somites, 4 somites, 10 somites, 24hpf, 30hpf, 48hpf, 72hpf.  All the 
embryos were fixed in 4% paraformaldehyde/PBS for 2 days at 4°C.  If necessary, the 
embryos were dechorionated with fine point tweezers in PBS and washed in methanol for 
10 min at room temperature.  Methanol wash was followed by dehydration in methanol, 
and stored at -20°C for in situ hybridization.  Digoxigenin-labeled riboprobes were 
generated according to the manufacturer’s protocol (Roche, Indianapolis, IN, USA).  
Whole mount in situ hybridization was performed in an InSituPro VSi liquid handler 
(Intavis Inc, Chicago, IL, USA).  Embryos stored in -20°C were subjected to pre-chilled 
acetone treatment at -20°C for 10min.  Acetone was replaced by methanol and embryos 
were incubated at room temperature for 10 min.  Embryos were then washed in methanol 
twice at room temperature.   Embryos were then rehydrated in steps starting with 50% 
methanol/PBS (5 min), 30% methanol/PBS (5 min), PBS (2 x 5 min), and PBTw (PBS + 
1 gram of bovine serum albumin + 0.1% Tween-20) (2 x 5 min).  Embryos were then 
hybridized at 65°C for 12-14h with riboprobe diluted 1:500 in hybridization buffer (50% 
formamide, 2x SSC, 0.1% tween-20, 5mM EDTA, 0.1% CHAPS).  Embryos were then 
washed with 50% formamide, 2x SSC/0.3% CHAPS (2 x 30 min, 65°C), 2x SSC/0.3% 
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CHAPS (2 x 15 min, 65°C).  Specimens were then blocked with (5 % sheep serum 
(Sigma), 2% blocking reagent (Roche)/MAB) and incubated with embryo-adsorbed anti-
digoxigenin, fab fragments antibodies coupled to alkaline phosphatase (Roche), 1:2000 
in 5% sheep serum/PBT.  Embryos were then washed 9-11 x 20 min with PBTw.  The 
embryos were washed with staining buffer (100mM Tris-HCl pH 9.5, 100mM NaCl, 50mM 
MgCl2, 0.1% Tween 20) twice for 5 min at room temperature. Embryos were next placed 
in 6 well plates and incubated with substrate BM Purple overnight at 4°C (Roche Inc.).  
Stained embyros were fixed in 4% PFA and photographed using BX51 compound 
microscope with UPLFLN 20x/0.5 objective and DP71 camera (Olympus).  All figures 
represent embryos that were simultaneously processed for fixation and staining.  The 
following antisense riboprobes were generated scl (Liao, Paw et al. 1998), hand2 (Yelon, 
Ticho et al. 2000), nkx2.5 and gata4 (Chen and Fishman 1996).   
2.11 TGFβR1 INHIBITOR TREATMENT 
Tgfbr1 inhibitor LY-364947 (Calbiochem) was solubilized in pure DMSO to 20mM final 
concentration.  For treatment of morpholino injected embryos LY-364947 was diluted in 
zebrafish fish water containing 1mM Tris-HCL pH 7.4, 1% DMSO, 1x 30% Danieau buffer, 
0.003% 1-phenyl-2-thiourea (PTU) to have working concentration of 10µM. From the 
10µM working concentration further dilutions were made and embryos were exposed to 
(0µM-1µM in 1% DMSO) LY-364947 beginning at different time regimes starting with 6 
hpf and examined at 48hpf.  Treatments were carried out in 6 well-plates.  
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3.0  RESULTS 
3.1 ZEBRAFISH FIBULIN-4 GENES 
Zebrafish have two paralogous genes for fibulin-4, fbln4a and fbln4b.  Comparative 
analysis of the fbln4 gene structure, the transcripts and the amino acid sequences of the 
human and zebrafish fibulin-4s shows a relatively high level of conservation. All three 
genes (human FBLN4 and zebrafish fbln4a and fbln4b) have 11 exons where the first is 
a non-coding exon. The three genes differ mostly in the sizes of the introns and the length 
of the 3’-untranslated region (Figure 6A). The pairwise amino acid sequence identity 
among the three fibulin-4 proteins is high (65-73%, Figure 6B), with the exception of a 
unique insert within the first calcium-binding epidermal growth factor-like (cbEGF) domain 
highlighted in the multiple alignment (Figure 7A). These unique peptides have been used 
as antigens to generate antibodies against the Fbln4a and Fbln4b proteins.  Given that 
Fbln4a was slightly more similar (68%) to the human FBLN4 protein than Fbln4b (65%), 
it is more likely to be the ortholog of human FBLN4 and therefore I focused my subsequent 
studies on Fbln4a.   
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Figure 6.  The structure of zebrafish fibulin-4 genes.  
(A) The human and zebrafish fibulin-4 genes drawn to scale (cartoons) and key characteristics of 
each gene (table).  The following transcripts with Ensembl (and RefSeq) identification numbers 
are represented: Dr. fbln4a: ENSDART00000134098.1 (NM_001008587); Dr. fbln4b: 
ENSDART00000139460.2; Hs. FBLN4: ENST00000307998.6 (NM_016938). Horizontal lines: 
introns; long vertical bars: exons; short vertical bars: non-coding exons; Dr: Danio rerio; Hs: Homo 
sapien; kb: 1000 (kilo) base pairs; aa: amino acid residues. (B) Percent identity of the human and 
zebrafish fibulin-4 proteins compared by multiple sequence alignment. 
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Figure 7.  Fbln4a protein structure and sequence alignment. 
(A) Domain structure of the fibulin-4 protein. (B) Multiple alignment of the human and zebrafish 
fibulin-4 proteins, with protein accession numbers listed next to the protein name. Non-conserved 
amino acids are highlighted in pink and represented by stars in the consensus sequence. The 
peptide sequences used as antigens for antibodies against Fbln4a and Fbln4b are in blue boxes. 
Dashes show missing amino acids. Colored bars underneath the consensus sequence indicate 
fibulin-4 domains using the same color scheme as in panel A. 
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3.1.1 Developmental expression of zebrafish fibulin-4 RNA 
To understand the role of fibulin-4 in embryogenesis, we first investigated how early the 
zebrafish fbln4 genes are expressed.  We performed semi-quantitative reverse 
transcription PCR (RT-PCR) for both zebrafish fbln4 genes starting from one-cell stage 
to germ ring stage by using beta actin expression as a control (Figure 8).  The reason we 
selected these stages is because the zygotic transcription starts by germ ring stage.  
Thus, one can differentiate between maternal transcripts and zygotic transcripts. The 
results for the RT-PCR showed that both fbln4a and fbln4b mRNA were present 
throughout this early developmental period.  Because zygotic gene expression in 
zebrafish does not start until the mid-blastula transition (between the 1000 cell and germ 
ring stages), our results show that both fbln4 genes produce maternal transcripts.   
 To further investigate the temporal and spatial expression patterns of fbln4a 
mRNA we collected wildtype zebrafish embryos at different stages and detected fbln4a 
expression by using whole mount in situ hybridization (WISH).  We analyzed fbln4a 
expression during embryonic development from 30% epiboly to 2 days post fertilization 
(dpf) in wildtype embryos (Figure 9).  WISH shows that fbln4a is a maternal transcript and 
localized to entire epiblast.  At 75% epiboly, the expression is seen in the margins of the 
epiblast and hypoblast. At tailbud stage, the expression becomes prominent in the head 
regions and adaxial cells (Figure 9C-D). By 10 somites, the gene expression intensity 
increases in the adaxial cells adjacent to the notochord and the expression is seen along 
the entire length of the notochord (Figure 9G-J).  At 24hpf, the fbln4a expression is seen 
in the head and in the myosepta, the connective tissue located between the muscle 
segments called myomeres (Figure 9K-L).  By 30hpf, the expression in the head remains, 
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whereas the expression in the myosepta gradually becomes restricted to the tail (Figure 
9M-N).  Finally, at 48hpf, expression was observed in the head and the whole heart 
(Figure 9O-P).  The presence of fbln4a transcripts in the adaxial cells close to the 
notochord suggests that the fbln4a gene is regulated by signals emanating from the 
notochord, perhaps the same signals that specify adaxial  cells, such as sonic hedgehog 
(Shh) and echidna hedgehog (Ehh) (Currie and Ingham 1996).  
 
 
 
 
 
 
 
 
Figure 8.  Developmental expression of the fibulin-4 mRNA.  
RT PCR analysis of the expression of fbln4a and fbln4b in unfertilized eggs and embryos up to 
the germ ring stage.  RNA was pooled from at least 30 embryos at each time point, and beta actin 
was used as a loading control. 1k=1000  
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Figure 9.  Developmental localization of fbln4a mRNA.  
Whole mount in situ hybridization shows fbln4a expression at various stages of development. (A)  
At 30% epiboly fbln4a mRNA is present throughout entire epiblast.  (B) At 75% epiboly the 
expression is concentrated on the margins of the epiblast (blue arrow) and hypoblast (red arrow). 
(C-F) At tailbud stage, the expression becomes prominently in the head (blue arrow) and in 
adaxial cells (red arrow) (G-J) During somitogenesis, expression remains in head (blue arrow) 
but is abundant in the adaxial cells (red arrow) throughout the length of the mesoderm up to the 
tail bud. (K-L) By 24hpf, the expression becomes dominant in the head (blue arrow) and 
posteriorly in the tail with higher expression in the vertical myosepta (red arrow). (M-N) At, 30hpf 
the expression fades away in the head and moves further posteriorly in the tail.  (O-P) By 48hpf 
there is no expression in tail but abundant in the head (blue arrow) and the heart (red arrow) 
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3.1.2 Developmental expression of zebrafish fibulin-4a protein 
We further investigated the developmental expression of the Fbln4a protein using whole 
mount immunostaining (WMIS) to study and compare protein expression to the mRNA 
expression (Figure 10).  WMIS of the wild type zebrafish embryos using anti-Fbln4a 
antibody revealed dynamic expression pattern of this protein throughout the development 
and delineated its presence during heart morphogenesis. At 30% epiboly, Fbln4a is 
expressed in the entire mesendoderm and matches completely the expression of the 
mRNA (Figure 10A). At tailbud stage Fbln4a is seen expressed in the axial mesoderm 
from the polster to the tail bud (Figure 10E-F). During segmentation, Fbln4a expression 
is maintained in the axial mesoderm and the notochord with more prominent signal in the 
polster (an anterior and lateral part of prechordal plate that underlies the forebrain during 
somitogenesis and gives rise to hatching gland) and tailbud cells than in the notochord 
(Figure 10G-L).  Dorsal and dorsolateral views of the embryo show brightly stained cells 
with localization consistent with the polster, which surrounds the forebrain in an arc 
(Figure 10M-P). Whether the Fbln4a protein expression is intracellular or extracellular 
was not determined conclusively although testing with DAPI staining suggested that 
Fbln4a is deposited in extracellular puncta surrounding the polster cells (data not shown). 
During somitogenesis Fbln4a is localized to the notochord during development. At 24 hpf 
Fbln4a is found over the entire notochord sheath (Figure 12).  Thus, I found Fbln4 protein 
to be localized to structures that express it with the two notable exceptions of the polster 
cells, which appear to sequester Fbln4 around them, and the notochord to which Fbln4 is 
bound following secretion by the adaxial cells.   
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Figure 10.  Developmental expression of the Fbln4a protein.  
Whole mount immunofluorescent staining (A, C, E, G, I, K and M-P) shows Fbln4a expression at 
various stages of development, with bright field images of the same embryos shown side-by-side 
for orientation (B, D, F, H, J and L) in lateral view with anterior to the left. (A, B) At 30% epiboly 
diffuse Fbln4a signal is seen throughout the epiblast. (C, D) By 75% epiboly Fbln4a is 
concentrated to the epiblast margins (red arrows) and the hypoblast of the head (blue arrow) to 
tail region. (E, F) At the tailbud stage the mesendoderm from head to tail is positive for Fbln4a. 
(G-L), During early segmentation, 2 to 10 somite (som) stages, Fbln4 is primarily localized to the 
head (blue arrow) and tail (red arrow) mesoderm. Dorsal (M-O) and dorsolateral (P) views of the 
head region show strong punctate labeling spreading posteriorly in an arc consistent with the 
polster (white dotted lines). 
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3.1.3 Validation of Fbln4a mutant embryos 
To generate a vertebrate model for FBLN4-related cutis laxa in which we could analyze 
both embryogenesis and later stages of development, we obtained a zebrafish mutant 
containing a retroviral insertion in exon 2 of fbln4a gene (Figure 11A). The insertion 
breakpoints were validated by PCR amplifications across each insertion breakpoint and 
DNA sequencing (Figure 11A). Based on these data, a 3-primer genotyping assay was 
designed which accurately and robustly distinguished the mutant and wild type alleles in 
all three genotypes (Figure 11B).  
RT-PCR of fbln4a across the insertion site produced no product in homozygous 
mutant embryos (Figure 11C,D), however, RT PCR products covering exons downstream 
of the insertion site showed equal intensity in WT and mutant samples        (Figure 
11C,E,F), suggesting that the retroviral insertion did not affect the stability of the mutant 
RNA.  Nevertheless, immunoblotting of the homozygous mutant embryos at 24hpf and 
48hpf  indicated that protein expression was completely lost in this line herein referred to 
as fbln4a-/- (Figure 11G).   A likely explanation for the lack of Fbln4a protein in our mutant 
animals is that the signal peptide is absent from the predicted mutant protein (Figure 
11H).  Without the signal peptide Fbln4a cannot enter the endoplasmic reticulum (ER) 
and will likely be incorrectly folded and unstable in the absence of the required 
chaperones and redox molecules residing in the ER.  Alternatively, the mutant mRNA 
may be poorly translated, as it lacks a sufficiently strong match to the Kozak sequence 
(gccgccRccAUGG) (Kozak 1987) required for the recognition of the translation initiation 
site by ribosomes.   
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We further validated the fbln4a-/- mutants by performing WMIS on the embryos 
obtained from heterozygous parents.  WMIS followed by confocal microscopy showed 
colocalization of Fbln4a with a notochord marker, wheat germ agglutinin in control 
embryos at 24hpf, but Fbln4a was lost from the notochord sheath in fbln4a-/- animals             
Figure 12.  In summary, the zebrafish retroviral mutant line lacks any functional Fbln4a 
protein, and thus is a null mutant.   
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Figure 11.  Validation of fbln4a retroviral insertion mutant.   
(A) A diagram showing the location of the retroviral insertion downstream of the fbln4a start codon. 
Primers used for genotyping zebrafish embryos are indicated.   (B) Genotyping of fbln4a +/+, +/-
, -/- embryos.  (C) Location of primer pairs used for RT-PCR on a diagram of the fbln4a transcript. 
RT-PCR products amplified between exons 1-3 (D), exons 4-6 (E), and exons 8-10 (F) from 
fbln4a+/+, fbln4a+/- and fbln4a-/- embryos. (G) Western blotting of fbln4a+/+ and fbln4a-/- zebrafish 
embryos. (H) A schematic view of the predicted protein products of  the wildtype and mutant 
alleles. 
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Figure 12.  Validation of fbln4a retroviral insertion mutant by whole mount 
immunostaining. 
Confocal image of the whole mount immunostained embryos for Fbln4a antibody (green) which 
shows localization of the protein in the notochord sheath at 24hpf.  Wheat germ agglutinin which 
stains the notochord was used as control (red). 
 
3.1.4  fbln4a mutants does not exhibit any obvious phenotype 
Homozygous fbln4a-/- mutant embryos obtained by breeding heterozygous parents 
displayed no noticeable morphological abnormalities compared to wildtype up to at least 
9 days post fertilization (Figure 13). Furthermore, as a quantitative variable relevant to 
cardiovascular health we measured the heart rates of all the embryos obtained from the 
heterozygous breeding and later genotyped the embryos.  We did not observe any 
significant difference in the heart rates between fbln4a-/- embryos or the fbln4a+/+ embryos 
(Figure 13B).  At 6dpf, the mutants developed normal swim bladder just like the wildtype 
equivalent embryos.   Moreover, the offspring from heterozygous parents were raised to 
adulthood and tail-clipped for genotyping at 3 months and we observed no statistically  
significant deviation from the expected Mendelian ratios (Figure 13C).  The adult 
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homozygous fish were in-crossed to obtain all homozygous offspring and we found that 
all the embryos were viable and fertile up to 1 year, suggesting that fbln4a mutant 
embryos have complete gene compensation for the loss of fbln4a (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Zebrafish fbln4a mutant embryos do not exhibit any obvious 
phenotype.  
 (A) There are no obvious morphological differences between fbln4a homozygous embryos and 
wildtype embryos up to 9 days and beyond up to adulthood (not shown). (B) No significant 
difference in the heart rates was observed  between fbln4a+/+ and fbln4a -/- offsprings obtained 
from heterozygous parents at 48hpf (n=20, unpaired t-test). (C) At 4 months, offspring from 
heterozygous parents maintained mendelian ratios.  The χ2 statistic has been calculated to assess 
significant difference between expected and observed Mendelian ratios of wildtype, heterozygous 
and homozygous embryos, observed no significant difference ( P = 0.1884).  
 
 
Genotype 
4 months 
fbln4a+/+ fbln4a+/- fbln4a-/- 
Number 
Percent 
42 
(31%) 
65 
(49%) 
27 
(20%) 
 
A 
B 
C 
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3.1.5 The protein product of the maternal fbln4a mRNA is present up to the 
tailbud stage 
To investigate the persistence of the protein product of the maternal fbln4a mRNA, we 
compared embryos derived from heterozygous breeding to ones derived from 
homozygous breeding by performing WMIS for Fbln4a.  We found that homozygous 
embryos derived from heterozygous breeding had maternal protein present up to the 
tailbud stage, but no Fbln4a was seen in embryos derived from homozygous breeding 
Figure 14.  At 10 somite stage specific staining in the notochord was absent in the      
fbln4a-/- embryos obtained from both breeding schemes. Thus, we conclude that maternal 
Fbln4a may contribute to zebrafish development up to the tailbud stage, but zygotic 
Fbln4a is abundantly present during segmentation.  
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Figure 14.  Maternal Fbln4a is present up to tail bud stage.  
fbln4a-/- embryos obtained by breeding heterozygous parents show presence of maternal Fbln4a 
protein up to tailbud stage (blue and red arrows).  fbln4a-/- embryos obtained by 
breeding homozygous parents do not show expression of Fbln4a protein at any stage of 
development.   
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3.1.6 Validation of fbln4a morpholino knockdown 
To further investigate the developmental consequences of Fbln4a deficiency, we 
performed transient loss-of-function experiments using antisense morpholino 
oligonucleotide-mediated gene knockdown. We designed splice-blocking morpholino 
oligonucleotides to target the intron 3 donor site of fbln4a and the donor site of intron 4 of 
fbln4b as a negative control (Figure 15A).  RT-PCR analysis and DNA sequencing of 
morphant embryos demonstrated complete skipping of exon 3 of fbln4a up to 24 hpf and 
partial skipping at 48hpf (Figure 15B).  Exon3 skipping results in a frameshift and 
premature termination of translation yielding a premature stop codon in exon 4 resulting 
in truncated protein which would likely be dysfunctional. Immunoblotting for Fbln4a in 
morphant embryos showed that there is a 96% reduction in protein expression at 24 hpf 
and 89% reduction at 48 hpf in comparison to control morpholino injected embryos 
(Figure 15C). We further validated the knockdown effect by performing WMIS in 
morphants and we found that the Fbln4a protein was completely absent from the 
notochordl sheath (Figure 16).    
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Figure 15.  Validation of morpholino knockdown of fbln4a by RT-PCR and 
immunoblotting. 
(A)  Design of the exon skipping strategy used to target the zebrafish fbln4a and fbln4b genes by 
injecting antisense morpholino oligonucleotides (MO) targeting splice sites.  (B) RT-PCR analysis 
of fbln4a and fbln4b MO embryos showed a smaller product than controls (ConMO) as a result of 
exon skipping.  Beta actin was used as a loading control.  (C) Immonoblotting confirmed the 
knockdown at the protein level, with beta actin as a loading control.  Relative protein Fbln4a 
normalized to actin and the control samples are shown below the immunoblot image. 
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Figure 16.  Validation of morpholino knockdown of fbln4a by whole mount 
immunostaining.      
Epifluorescent images of control morpholino injected embryos (A-B) show colocalization of 
Fbln4a immunostaining (A) and wheat germ agglutinin (WGA) staining (B) in the notochord 
sheath. In contrast, fbln4a morpholino injected embryos lack Fbln4a in the notochord (C), which, 
however, does stain with WGA (D) Non-specific staining is seen in the yolk sac in all images.  
Scale bars: A-B 1 mm; C-D 2 mm.  Presence or absence of notochord staining marked by blue 
arrow 
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3.1.7 Transient knockdown of fbln4a exhibit cardiovascular defects 
Based on pilot dose-response studies we found that the injection of 5 ng of fbln4a MO 
into wildtype zygotes produced a consistent phenotype characterized by a variety of 
cardiovascular abnormalities at 2 days post fertilization (dpf) (Figure 17D). Injection of the 
same amount of non-target control MO produced no phenotypes (Figure 17A). In addition, 
the fbln4a MO treated embryos suffered from reduced circulation, pooling of blood in the 
caudal vein plexus or around the heart, cardiac and hindbrain edema, vascular 
hemorrhage in the head, and underdeveloped segmental vessels by 48 hpf. The 
morphant embryos had a significantly (p< 0.0001) reduced average heart rate of 80-85 
beats per minute compared to control MO injected embryos, which had average heart 
rate of 125 beats per minute (Figure 17G). Musculoskeletetal anomalies included reduced 
embryo length, curved tail and rounded somites Figure 18. Knockdown of fbln4a results 
in rounded myomeres. Despite a multitude of developmental anomalies, the survival of 
the morphant embryos was normal (Figure 17H).   
To test the specificity of the observed phenotypes, we performed overexpression 
and rescue studies by injecting fbln4a and control mRNA into fertilized eggs. Injection of 
100 ng fbln4a mRNA produced strikingly similar phenotypes to fbln4a MO, including blood 
pooling in the tail, pericardiac and hindbrain edema, and curved tail (Figure 17E), but did 
not affect survival.  The injection of 100 ng mCherry (control) mRNA did not affect normal 
development (Figure 17B).  However, co-injection of fbln4a mRNA with the MO rescued 
the morphant phenotype yielding 70% normal embryos (Figure 17E). These experiments 
provide two lines of evidence to support the specificity of the fbln4a morphant phenotype: 
(1) the ability to rescue the effect of MO knockdown by mRNA injection, and (2) the 
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similarity of the knockdown and overexpression phenotypes. Indeed, similar phenotypes 
have been observed for gain and loss of function mutations in both humans (Zweier, Sticht 
et al. 2007) and zebrafish (Kabashi, Lin et al. 2010) 
Figure 17.  Knockdown and rescue of embryos injected with fbln4a MO.  
Injection of 5 ng control (Con) MO (A), 100 pg of control mRNA (B), or the combination of the two 
(C) did not affect the development zebrafish embryos. In contrast both injection of 5 ng fbln4a MO 
(D) and fbln4a mRNA (E) results in embryos with a range of cardiovascular  and connective tissue 
abnormalities including blood pooling (arrow head) hindbrain edema (arrow head) and curved tail. 
In contrast the co-injection of fbln4a MO and mRNA rescued the embryos (F). In all panels, head 
faces left and dorsal is up.  Scale bars: 1 mm. The dose and the composition of the mRNA and 
morpholinos are indicated on the images. (G) The heart rate of control (Con) and fbln4a MO 
injected embryos were recorded in beats per minute (bpm) units. ****p=0.0001  (H) Quantification 
of embryos in percentages with normal, abnormal and dead categorization.  The number of 
embryos assessed in each group is shown below each bar. All data were collected at 48hpf. 
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Based on the early expression of fbln4a in relevant tissues, such as the paraxial and head 
mesoderm, we hypothesized that the observation of late stage cardiovascular phenotype 
might be a consequence of impaired specification of cardiovascular progenitors located 
in the lateral plate mesoderm whose expression is initiated during somitogenesis. In the 
fbln4a morphant embryos the expression of hand2, which marks the entire zebrafish heart 
forming region (HFR) (Yelon et al. 2000) is expanded both in the anterior and posterior 
directions (Figure 19C-D). The expression of the heart-specific transcription factors such 
as nkx2.5 and gata4 were increased (Figure 19A-B, G-H).  In contrast, expression of the 
scl, a marker of hematopoietic and vascular progenitors (Liao et al. 1998) showed 
decreased and disorganized expression pattern (Figure 19E-F). Our findings suggest that 
Fbln4a limits cardiac and enhances vascular cell fates. 
 
 
 
 
 
 
 
Figure 18. Knockdown of fbln4a results in rounded myomeres. 
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Figure 19.  Knockdown of fbln4a disrupts the fate decision of cardiovascular 
progenitors during somitogenesis. 
The expression of nkx2.5 (A, B) hand2 (C, D) scl (E, F) and gata4 (G, H) were assessed by in 
situ hybridization in embryos injected with 5 ng of control (Con) or fbln4a MO. The embyos are 
oriented to show the anterior lateral plate mesoderm in dorsal view. Overlapping parts of the heart 
field are marked by nkx2.5, hand2, and gata4, and show expansion in morphant embryos, wheras 
scl marks the blood and vessel progenitors which are reduced and abnormally positioned in 
morphants.  The proportion of embryos showing the indicated changes are shown in the bottom 
right corner of each image.     
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3.1.8 Fbln4a heterozygous embryos are sensitized to, but homozygous mutants 
are resistant to MO treatment  
To further investigate the molecular basis of the lack of phenotype observed in fbln4a 
mutants, and provide additional evidence for the specificity of the morphant phenotype 
we injected fbln4a MO into fbln4a+/+, fbln4a+/-, and fbln4a-/- embryos and assessed the 
consequent phenotypes at 48hpf. Wildtype embryos injected with low dose (3ng) of fbln4a 
MO did not exhibit any noticeable gross abnormalities (Figure 20B), whereas we 
observed characteristic cardiovascular and connective tissue defects in fbln4a+/+ embyros 
injected with the optimal dose of  5ng fbln4a MO (Figure 20C), similar to earlier results. 
Unlike in wildtype embryos, 3ng MO treatment led to the development of anomalies in 
55% of fbln4a+/- heterozygotes (Figure 20E) including shortened body axis, pericardiac 
and caudal blood pooling and hindbrain edema (Figure 20L-N) whereas 5ng MO dose 
resulted in anomalies of similar severity and frequency of as in fbln4a+/+ embyros (Figure 
20F).  Homozygous embryos obtained by breeding homozygous adult parents did not 
show any abnormalities at any morpholino concentration (Figure 20G-I).  Quantitative and 
statistical analysis showed highly significant (p<0.0001) differences between phenotype 
frequencies in fbln4a+/- embryos treated with 3 ng MO compared to either fbln4a+/+ or 
fbln4a-/- fish with the same treatment (Figure 20O), as well as fbln4a-/- fish injected with 
5ng MO compared to fbln4a+/+ and fbln4a+/- embryos injected with the same dose of MO.   
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In summary, we identified an optimal dose of the fbln4a MO, which had no effect on fbln4a 
mutant embryos but caused clear cardiovascular defects in the WT, indicating that the 
morphant phenotypes were specific and not due to off-target effects, which are expected 
to be detected in fbln4a-/- animals. The observation of a phenotype at low doses in the 
heterozygous embryos which contain half as much fbln4a further supports the specificity 
of fbln4a MO. The lack of MO phenotype in fbln4a-/- embryos suggest that the discrepancy 
in mutant to morphant phenotype can be due to activation of compensatory 
developmental genes or pathways in homozygous mutants. Thus, the results validate the 
specificity of both the mutation and the MO reagent.  
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Figure 20.  Effect of fbln4a morpholino on wildtype, heterozygous and 
homozygous embryos.   
Gross morphology of fbln4a+/+ (WT) (A-C), fbln4a+/- heterozygous (D-F), and fbln4a-/- homozygous 
(G-I) embryos injected with 0 (A, D, G) , 3 (B, E, H) and 5 ng (C, F, I) of fbln4a MO. Higher 
magnification images of the head (J, L) and tail (K, N) illustrating normal morphology in WT 
embryos (J, K) and cardiac and hindbrain edema and tail blood pooling (arrowheads) in 
heterozygous embryos injected with 3 ng of fbln4a MO (L, N). In all panels, head faces left and 
dorsal is up.  Scale bars represent 250µm in panels A-I, and 100µm in panels J-N.  All the embryos 
at 50hpf.  Quantitatvie analysis of the frequency of developmental anomalies in untreated and 
MO treated fish with different genetic backgrounds (O). Pairwise χ2 tests were used to compare 
counts of abnormal embryos  between the groups  (∗∗∗p< 0.0001, NS- not significant). The total 
number of embryos assessed in each group is shown below each bar. 
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3.1.9  Rescue of fbln4a morphants by Tgfbr1 inhibition  
Because elevated TGFβ signaling has been shown in aortic and lung tissues of human 
patients with FBLN4 recessive mutations (Renard, Holm et al. 2010), we adopted a 
pharmacological approach to evaluate the effect of zebrafish fbln4a knockdown on Smad 
dependent canonical TGFβ pathway. For this we decided to inhibit TGF receptor 1 
(Tgfbr1) kinase activity using a small molecule inhibitor, LY-364947 through which the 
canonical signaling takes place.  We chose this chemical genetic approach because there 
are 2 tgfbr1 genes in zebrafish, tgfbr1a and tgfbr1b. With the use of LY-364947 we are 
able to inhibit both paralogs with 1 drug as kinase domains of both proteins is highly 
conserved.  We used LY-364947 because it specifically targets the Tgrbr1 kinase function 
and which is, in contrast to other Tgfbr1 inhibitors, much less potent against related 
kinases such as Tgfbr2 (Singh, Chuaqui et al. 2003, Li, Wang et al. 2006) and has been 
previously shown to be effective in targeting canonical TGFβ signaling in zebrafish 
embryos (Zhou, Cashman et al. 2011).  We employed an LY-364947 dilution series 
ranging from 0 to 1µM to ConMO to asses toxic effects or to detect any phenotypes at 
this range of concentration.  Treatment of ConMO injected embryos with 0.25µM, 0.5µM, 
0.75µM and 1µM of LY-364947 from 6hpf up to 48hpf had no effect on normal morphology 
of injected embryos as expected at 2dpf (Figure 21).  This is consistent with our previously 
published dose-response studies on LY-364947 treatment in zebrafish, which showed no 
phenotypic consequences with treatment concentrations up to 10µM (Willaert, Khatri et 
al. 2012).   However, fbln4a morphants treated with both 0.5 µM, 0.75 µM and 1µM LY-
364947 showed gross morphological rescue of  embryo length, blood circulation, no 
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caudal and heart blood pooling and normal head development when examined at 2dpf 
(Figure 21).  The dose-respose of the rescue experiments indicated 0.5 µM as the optimal 
concentration of LY-364947 required to reverse the morphological defects seen as a 
result of fbln4a loss. 
 
 
Figure 21.  Tgfbr1 inhibition rescues fbln4a morphants.  
A minimum of 50 ConMO (A) and fbln4aMO (B, C) injected embryos were used for each drug 
treatment.  A dilution series of LY364947 was used for the experiment to determine the optimal 
dose of the drug. Morphant embryos were rescued by 0.5-1µM LY364947.  Scale bar = 250µm. 
(D) The proportions of embryos with normal physiology shown as percentages at each drug 
concentration.   
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3.1.10  Identification of critical time regime for LY-364947 rescue 
In order to determine the critical time period during which manipulation of TGFβ signaling 
rescues fbln4a morphants, I performed drug treatment experiments for various periods of 
time (Figure 22).  As described above, treatment of fbln4a MO injected embryos starting 
from 6 hpf up to 48 hpf rescued 70% of the fbln4a morphants (Figure 21D).  Later, we 
divided the treatment periods into 2: 6-18 hpf and 18-48 hpf. The 6-18hpf treatment 
showed similar rescue percentage as 6-48 hpf while 18-48 hpf treatment did not show 
any rescue of fbln4a gross phenotype (Figure 23A,B).  Next, the time period of 6-14 hpf 
was again split into 2 four-hour treatments (6-10 hpf and 10-14 hpf) and 2 eight hour 
treatments (6-14 hpf or 10-18 hpf).  Out of all the 4 combinations only 6-14 hpf treatment 
showed rescue of fbln4a morphants (Figure 23C-F) which span gastrulation and 
somitogenesis stages of development.  These results suggest that role of  fbln4a in 
cardiovascular development via TGFβ signaling is stage dependent between gastrulation 
and segmentation. Further, testing of normalization of the abnormal cardiovascular 
markers is required to confirm direct relation between altered TGFβ signaling and 
cardiovascular development lesions in fbln4a morphants.  
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Figure 22.  The critical period for rescuing fbln4a morphants by Tgfbr1 inhibition.   
The time scale showing different time windows used for drug experiment as indicated in hours 
post fertilization. Green bars indicate rescue and red bars show no rescue.     
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Figure 23.  Quantification of LY-64947 treated fbln4a morphants.   
Graphical representation of the percentage of embryonic zebrafish with fbln4a specific 
abnormalities when treated by LY364947 drug was at 0.5µM and 1µM concentrations for 6-18 hpf 
(A), 18-48 hpf (B) 10-18hpf (C) 6-10 hpf (D) 10-14 hpf (E) and 6-14 hpf (F). The number of animals 
in each group is shown below the bars.  Pairwise χ2-tests were performed to compare groups 
(∗∗∗p< 0.0001). Monster: embryos with severe, non-specific anomalies. 
 
 75 
3.2 DISCUSSION 
In this study we describe for the first time the characterization of a stable fbln4a mutant 
zebrafish.  We find that, contrary to transient knockdown studies performed in this project 
showing role of fbln4a in cardiovascular development and studies performed by Zhang 
et. al 2015 showing role of fbln4a in convergent extension, homozygous fbln4a mutant 
embryos display no discernible convergent extension defects or cardiovascular 
abnormalities, survive into adulthood and are fertile.  These embryos have a straight body 
axis and no overt morphological abnormalities.  In contrast, transient knockdown embryos 
of fbln4a exhibit clear cardiovascular defects at 2 dpf including defects in blood circulation 
with reduced heartbeat, pooling of blood in the caudal vein plexus, and shortened body 
axis.  
3.2.1 Fbln4a and tendon development 
The expression of fbln4a in the myosepta as early as 24 hpf is remarkable. Vertical 
myosepta are tendons between the myomeres. A critical early differentiation marker of 
tendon cells is scleraxis-a (scxa) which starts to be expressed in the myosepta at 36 hpf.  
Therefore, fbln4a marks tendon progenitors prior to their differentiation to tenocytes. 
Interestingly, fbln4a morphants develop rounded myomeres by 48 hpf instead of the 
straight chevron-shaped muscle segments observed in wildtype fish (Chen and Galloway 
2014). These observations are consistent with the requirement of Fbln4a for tendon 
development. In situ hybridization for key markers of tendon development (scxa, xirp2a) 
at the appropriate stages (24, 36, 48, 72 hpf) in morphant and control embryos will need 
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to be performed to define the precise developmental stage at which Fbln4a is required 
for the formation of tendons. Consistent with our results implicating Fbln4a in tendon 
development, both people and mice with Fbln4 mutations develop joint laxity and 
contractures associated with the disorganization of tenocytes and abnormal collagen 
fibrillogenesis (Markova, Pan et al. 2016). 
3.2.2 Morphant and mutant phenotypic discrepancies  
There can be several possible explanations for the discrepancy between morphant and 
mutant phenotype, a phenomenon that is increasingly being recognized and observed by 
various research groups for different genes (e.g. pak4, megamind, ift88, flt4) in targeted 
mutants (Kok, Shin et al. 2015).  The discrepancies between mutant and knockdown 
approaches are not particular to zebrafish, but have also been seen in Drosophila and 
Arabidopsis (Yamamoto, Jaiswal et al. 2014, Gao, Zhang et al. 2015). The possible 
explanations for discrepancy include an unexpectedly non-pathogenic lesion, maternal 
contribution, gene compensation, and MO off-target effects. We have probed some of 
these possibilities in the fbln4a project.    
To address the issue of non-pathogenic lesion we have extensively validated the 
fbln4a retroviral mutant.   First, we identified retroviral genomic insertion site by 
sequencing the region of retroviral insertion.  Next, we validated the gene disruption of 
fbln4a at the RNA level by amplification of the exons through the region of retroviral and 
confirmed the loss of transcription exons 1 and 2 which code for the signal peptide, the 
Fbln4a protein. Without the signal peptide, the Fbln4a protein would not be secreted into 
the ECM.  WMIS confirmed that in fbln4a retroviral mutant the Fbln4a protein was not 
 77 
detectable either as a result of inefficient translation or reduced protein stability. This 
finding rules out the possibility of residual protein function that can arise due to alternative 
splicing or any unanticipated functions of truncated proteins.   Thus, by thorough 
validation we have convinced ourselves that this retroviral mutant is a complete loss of 
function or null mutant.  Therefore, the lack of phenotype observed in mutants can either 
due to maternal transcript of fbln4a or due to compensatory effects as yet unidentified.  
To test the possible protective effect of Fbln4a maternal protein in rescuing the null 
mutants from any morphological defects, we tested the embryos for presence of Fbln4a 
protein by WMIS during early developmental stages.  The results showed presence of the 
Fbln4a protein up to tailbud stage which suggests that if Fbln4a had an important role 
during gastrulation as suggested by Zhang et. al, the maternal protein would compensate 
for it and help in normal gastrulation processes in the mutant embryos. However, we were 
able to in-cross homozygous adults to obtain all normal homozygous offspring and grow 
them upto adulthood suggesting that compensatory mechanisms in the fbln4a mutant 
overshadow the maternal effect of Fbln4a protein.    
Gene compensation has been documented to be one of the reasons for phenotypic 
discrepancies between morphants and mutants.  An example of such a scenario is study 
of egfl7 gene, where a null mutation in humans causes a mild partially penetrant defect 
in vascular stability, while wild type zebrafish embryos injected with egfl7 morpholino 
exhibit vascular morphogenesis defects.  However, egfl7 mutant embryos are protected 
from the effects of egfl7 MO, due to compensatory effect by upregulated adhesion 
molecules only in the mutants due to the genetic loss of egfl7 (Rossi, Kontarakis et al. 
2015).  A similar scenario may exist for fbln4a retroviral mutant embryos but further 
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experimental work is needed to identify the reasons for lack of any cardiovascular 
phenotype by identifying the type of compensation for fbln4a. One possible way of 
compensation could be redundancy of fbln4a gene with fbln4b, the other isoform of 
zebrafish fbln4.  This could be done by checking the expression levels of fbln4b gene in 
homozygous embryos quantitatively by qPCR and by immunoblotting.  Alternatively, we 
could try inject fbln4b morpholino at different doses into fbln4a homozygous retroviral 
mutant and check if we observe any phenotype at lower doses.    Also other compensatory 
genes or pathways which may potentially be playing protective role could be identified by 
performing and comparing transcriptome profiling of the knockdown embryos and 
homozygous mutant embryos to determine the possible explanation for phenotypic 
discrepancies.   
In forward mutagenesis screens, adopted for zebrafish have been successful, with 
focus on cardiovascular phenotypes, compensatory mechanisms do not appear to come 
to be activated in many mutants (Stainier, Fouquet et al. 1996).  However, it must also be 
noted that  in certain large-scale zebrafish mutagenesis studies only 6% of disruptive 
mutations in protein-coding genes have induced an observable phenotype 
(Kettleborough, Busch-Nentwich et al. 2013).    
3.2.3 Specificity of MO effects 
While MOs have been considered a landmark advance for their ease of usage in model 
organisms, problems with their application in zebrafish embryos emerged around 
2010/2011. Most notably, MOs induce p53-dependent (tumor suppressor) apoptosis in a 
sequence-independent manner (Robu, Larson et al. 2007).  However, not much is known 
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concerning the mechanism by which MOs induce p53 activation.  Consequently, some 
researchers have started injecting p53 MOs to suppress the cell death effect but then the 
results interpreted are not in wild type background but on a background lacking p53.  For 
our fbln4a project we have adopted an alternative approach to address this issue of 
possible off target effects of the fbln4a MO.  We decided to utilize our non-phenotypic 
fbln4a mutant embryos by injecting optimal doses of fbln4a MO into them and comparing 
the MO effect between WT and homozygous backgrounds. We found that even at optimal 
dose of MO the homozygous embryos exhibit no cardiovascular defects as seen in the 
wildtype background, suggesting we do not activate p-53 inducing off target effects by 
use of MO and the effect is specific in the wildtype background.  Conversely, the 
heterozygous embryos showed more susceptibility to the MO effects as they exhibit 
cardiovascular defects even at lower dosage with half as much genetic material further 
establishing the specificity of the MO reagent.  In summary, we have established that 
morpholino effects we observe in heterozygous and wildtype embryos are specific for the 
loss of fbln4a function.  These experiments also implicate molecular compensatory 
mechanisms as the most likely explanation for the lack of phenotype in the fbln4a mutant 
fish.   
3.2.4 Fbln4a and TGFβ signaling 
The range of phenotypes seen in fbln4a morphants such as defective blood circulation, 
blood pooling in the caudal vein and vascular hemorrhage could be reversed by using 
TGFBR1 inhibition. This suggests that in the fbln4a morphant embryos there is an 
increase in TGFβ signaling.   The rescue of the fbln4a morphants is stage dependent and 
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takes place only when TGFBR1 inhibition treatment is administered in the time window 
of 6hpf-14hpf spanning the gastrulation and somitogenesis stages in the zebrafish 
embryo. The heart and vascular morphogenesis begins at the end of gastrulation. The 
gene expression studies for fbln4a showed its expression in the prechordal plate at tailbud 
stage, in the adaxial cells adjacent to notochord during somitogenesis and in the heart at 
24hpf-48hpf.   The tgfb2 gene is expressed in the prechordal plate at tailbud stage and in 
the notochord during the somitogenesis which exactly matches the expression pattern of 
fbln4a gene expression supporting the hypothesis that fbln4a may directly or indirectly 
regulate TGFβ ligands. The tgfb3 gene is not detectable during gastrulation, but is active 
in the notochord during somitogenesis (1-13 somites) and in both the heart and notochord 
from at 24hpf (Cheah, Jabs et al. 2005).  
Expression of all the TGFβ1/2/3 R-smads (Smad2, Smad3) and Smad4 transcripts 
through which TGFβ signaling takes place is seen since blastula as a consequence of 
maternal origin (Dick, Mayr et al. 2000).   However, during gastrulation, they are either 
expressed at low levels or not detectable (smad3a and smad3b), while from tail bud 
stages the mRNA production increases.  The expression smad2 and smad4 is seen 
throughout the entire embryo, but particularly in the head and tail (Hsu, Lin et al. 2011).    
Overlapping gene expression pattern of fbln4a and tgfb2 and tgfb3 ligand genes suggest 
possible genetic interaction between these components and further experiments need to 
be performed to establish the link.   
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3.2.5 Evolutionary fate of fibulin-4 paralogs 
Many human genes have two paralogs in zebrafish as a result of a genome duplication 
that occurred in the common ancestor of teleosts approximately 320-350 million years 
ago (Glasauer and Neuhauss 2014).  Given the extensive evolutionary time that elapsed 
since this genome duplication event, all non-essential gene duplicates have been lost. 
The remaining gene duplicates mostly evolved through subfunctionalization to undertake 
parts of the original gene function by assuming complementary expression patterns 
(Glasauer and Neuhauss 2014).  However, some of the gene duplicates diverged by one 
of the two assuming a new function (neofunctionalization) occasionally by acquiring new 
protein domains (Kassahn, Dang et al. 2009).  In some cases, both copies are retained 
with the same expression patterns and function to ensure correct expression level 
(dosage selection). Certain gene ontology (GO) functional groups have preferentially 
retained both paralogs, including genes involved in integrin signaling and growth factor 
activity (Kassahn, Dang et al. 2009).  Given that fibulin-4 is involved in growth factor 
regulation, it is not surprising that both paralogs have been retained in zebrafish. 
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4.0  CONCLUSION 
In summary, our work shows that even in the face of clear evidence of a potentially 
disruptive loss of function mutation of fbln4a in zebrafish mutants, it is difficult to be 
unearth the role of this gene during embryonic development due to either maternal 
contribution or compensatory genes.   However, the non-phenotypic retroviral mutant can 
act as a resource to test and establish the specificity of fbln4a morpholino since it lacks 
the target for the morpholino. Transient knockdown of fbln4a by morpholino exhibits 
specific cardiovascular defects in wildtype embryos which can be reversed by stage 
dependent inhibition of TGFβ signaling using TGFBR1 receptor inhibitor drug suggesting 
increased TGFβ signaling in knockdown embryos.  However, further molecular testing of 
the TGFβ ligand, receptor and downstream target genes is required to prove the detailed 
mechanisms of TGFβ regulation by Fbln4a. 
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4.1 FUTURE WORK 
4.1.1 Quantitative PCR analysis of TGFβ related genes in morphants and 
mutants 
Based upon the observation  that Tgfbr1 inhibitor drug treatment of fbln4a knockdown 
embryos at 0.5 µM or 1µM concentration rescues the morphants of their gross 
cardiovascular phenotype we would check for change in TGFβ receptors, ligands and 
target genes by quantitative PCR (qPCR).  
Endpoints:  qPCR for (1.) TGFβ receptor genes : transforming growth factor beta2 
(tgfbr2), transforming growth factor beta 1a (tgfbr1a), transforming growth factor beta 1b 
(tgfbr1b).  (2.)  TGFβ target genes : col10a1, matn1, shox2, ctsh, smad6 and smad7 (3.)  
TGFβ ligand genes : transforming growth factor beta 1a (tgfb1a), transforming growth 
factor beta 2 (tgfb2) ,  transforming growth factor beta 3 (tgfb3). 
Method: The optimal dose of morpholino (5ng/embryo) would be injected into wild type 
embryos for transient knockdown.  I would collect 50-60 embryos of fbln4a morphants at 
tailbud and 10 somite stage for RNA extraction. Following house keeping genes would 
be used: elf, gapdh, and bactin1.    3 biological replicates would be used for the 
experiment.   
Expected results: We expect to see change in the gene expression for at least some of 
the components of the TGFβ pathway at the mRNA level.  
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4.1.2 RNA profiling analysis to identify the pathways activated by fbln4a 
deficiency & developmental compensation 
The aim of this study would be to compare the transcriptome profile of fbln4a morphant 
and mutant embryos at 3 different developmental stages using RNA sequencing to 
identify gene expression profile.  Also we would compare the embryos with and without 
the TGFβR1 inhibition to be able to compare the how the fbln4a morphant embryos are 
affected by TGFβ inhibition at the molecular level.   Since RNA Sequencing does not rely 
on predefined probes, it allows for an unbiased discovery of new transcripts in the 
experiment of choice.  This will allow us to identify the molecules underlying the different 
phenotypes observed in mutants versus the morphants at the same time explain the role 
of TGFβ inhibition in fbln4a morphant embryos.   
Endpoints:  Analysis of RNASeq results obtained after sending total RNA samples.    
Method:   The optimal dose of morpholino (5ng/embryo) will be injected into wild type 
embryos for injection.  I would collect 50-60 embryos of fbln4a morphants in 2 sets for 
RNA extraction at tailbud, 10 somite, and 48hpf stage. The 2 sets would include one with 
TGFβR1 inhibition and one without TGFβR1 inhibition.   Also I would collect 
corresponding 50-60 fbln4a-/- embryos from homozygous parents at tailbud, 10 somites 
and 48hpf stage to know which genes or pathways compensate in an event of loss of 
fbln4a.  RNA sequencing will be performed by sending collected RNA samples to 
Genomic Research Core at the University of Pittsburgh.   
Expected results: The results would better explain how does TGFβR1 inhibition rescues 
fbln4a morphant embryos at the molecular level.  Also the RNASeq experiment  would 
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help us identify the molecules or genes that play role in compensation for loss of fbln4a 
in the retroviral mutant for it to not show any phenotype.   
4.1.3 Testing cardiovascular markers in LY-364947 treated fbln4a morphants  
In light of the observation that knockdown of fbln4a gene in embryos exhibit change in 
early cardiovascular progenitors like hand2, scl and that drug treatment of ALK5 inhibitor 
in fbln4a morphants rescues the embryos of their gross cardiovascular phenotype it would 
be logical to check if Fbln4a serves as a link between TGFβ signaling and cardiovascular 
development.  In order to answer this question, I would have to check for normalization 
of cardiovascular markers in fbln4a knockdown embryos treated with LY-364947.  
Endpoints: WISH for hand2, scl, nkx2.5 for fbln4a morphant embryos at 10 somites 
(14hpf) treated with LY-364847 between 6hpf-14hpf.  
Method: The optimal dose of morpholino (5ng/embryo) will be injected into wild type 
embryos for transient knockdown.  Apply LY-364947 drug treatment starting from 6hpf-
14hpf and fix 50-60 fbln4a morphant embryos using 4% PFA at 10 somite (14hpf) stage 
for WISH.  
Expected results: If TGFβ plays role in regulating cardiovascular progenitors in fbln4a 
morphants then we would expect normalization of scl and hand2 markers upon  
LY-364947 treatment in comparison to untreated morphants. 
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